



US008278058B2

(12) **United States Patent**
Kim et al.

(10) **Patent No.:** **US 8,278,058 B2**
(45) **Date of Patent:** **Oct. 2, 2012**

(54) **DIAGNOSTIC COMPOSITION AND KIT FOR
RENAL CELL CARCINOMA**

(75) Inventors: **Dong Su Kim**, Daegu (KR); **Nam Hoon
Cho**, Seoul (KR); **Hyung Jin Na**,
Pohang-si (KR); **Young Deuk Choi**,
Seoul (KR); **Jae Ho Jang**, Busan (KR);
Hye-Kyung Kim, Gyeongju-si (KR);
Mo Yoel Park, Pohang-si (KR); **Won
Man Park**, Pohang-si (KR); **Tae-hoon
Kim**, Busan (KR); **Dong Hee Lee**,
Busan (KR); **Kyung Mok Park**,
Pohang-si (KR)

(73) Assignees: **DCD Inc.**, Pohang-si,
Gyeongsangbuk-do (KR); **Genomine,
Inc.**, Pohang-si, Gyeongsangbuk-do
(KR)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 224 days.

(21) Appl. No.: **12/672,498**

(22) PCT Filed: **Aug. 6, 2008**

(86) PCT No.: **PCT/KR2008/004562**

§ 371 (c)(1),
(2), (4) Date: **Feb. 5, 2010**

(87) PCT Pub. No.: **WO2009/020343**

PCT Pub. Date: **Feb. 12, 2009**

(65) **Prior Publication Data**

US 2010/0297661 A1 Nov. 25, 2010

(30) **Foreign Application Priority Data**

Aug. 6, 2007 (KR) 10-2007-0078436

(51) **Int. Cl.**
G01N 33/53 (2006.01)

(52) **U.S. Cl.** **435/7.1**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,162,504 A 11/1992 Horoszewicz
2006/0003368 A1 * 1/2006 Tacke et al. 435/6

OTHER PUBLICATIONS

Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
WIPO, International Search Report for International Application No.
PCT/KR2008/004562.

* cited by examiner

Primary Examiner — Sean Aeder

(74) *Attorney, Agent, or Firm* — Intellectual Property Law
Group LLP

(57) **ABSTRACT**

Disclosed herein are a composition and a kit for diagnosing
renal cell carcinoma. The composition and kit employ, as a
renal cell carcinoma marker, nicotinamide N-methyltrans-
ferase, L-plastin, secretagogin, NM23A, CapG, which is an
actin regulatory protein, and/or C4a anaphylatoxin.

9 Claims, 15 Drawing Sheets

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7






FIG. 8

FIG. 9



Protein annotation	Accession	Sequence coverage (%)	pI	MW	Est'd Z
nicotinamide N-methyltransferase	NP_006160.1	30	5.6	30.01	2.41

FIG. 10






FIG. 11




Protein annotation	Accession	Sequence coverage (%)	pI	MW	Est'd Z
secretagogin precursor	NP_008929.2	53	5.2	32.19	2.41

FIG. 12




Protein annotation	Accession	Sequence coverage(%)	pI	MW	Est'd Z
neurone-specific enolase	CAA31512.1	42	4.9	47.48	2.39

FIG. 13



Protein annotation	Accession	Sequence coverage(%)	pI	MW	Est'd z
Endothelial cell growth factor 1	AAH18180.1	36	5.4	30.36	2.35

FIG. 14



Protein annotation	Accession	Sequence coverage(%)	pI	MW	Est'd Z
ferritin light subunit	AAA52440.1	86	5.6	16.43	2.35

FIG. 15




FIG. 16






FIG. 17



Protein annotation	Accession	Sequence coverage(%)	pI	MW	Est'd Z
complement component 4A preproprotein: acidic C4: Rodgers form of C4: C4A anaphylatoxin	NP_009224.1	5	6.8	193.92	1.79

FIG. 18

DIAGNOSTIC COMPOSITION AND KIT FOR RENAL CELL CARCINOMA

CROSS-REFERENCE TO RELATED APPLICATION

This application is a U.S. National Phase application, under 35 U.S.C. §371, of International Application no. PCT/KR2008/004562, with an international filing date of Aug. 6, 2008, which is hereby incorporated by reference for all purposes.

TECHNICAL FIELD

The present invention relates to a composition and a kit for diagnosing renal cell carcinoma.

BACKGROUND ART

Tumors that develop in the kidney include renal cell carcinoma (in adults), Wilms tumor (in children) and uncommonly sarcoma.

Kidney cancer can be diagnosed through evaluation of imaging and biochemical tests. Imaging methods include computed tomography (CT) scanning and angiography. Biochemical evaluation involves using a probe such as an antibody that binds specifically to a diagnostic marker, which is a kidney cancer-specific protein or gene that is up- or down-regulated specifically in the tissues of kidney cancer.

Many biochemical diagnostic methods based on using a kidney cancer-specific mRNA or protein have been developed to detect renal cell carcinoma. For example, International Pat. Publication No. WO2005/024603 employs the differential expression of a gene between normal and tumor tissues. Lein, M. et al. suggested that MMP-2, which is over-expressed in kidney cancer, may be useful as a diagnostic marker of kidney cancer (International Journal of Cancer, 2000, Vol. 85, p 801-804). Also, TNFRSF7, which is expressed at high levels when renal function is abnormal, has the potential as a diagnostic marker for kidney cancer (Nakatsuji, T., Clinical and Experimental Medicine, 2003, Vol. 2, p 192-196). Other proteins which are overexpressed by kidney cancer and thus useful as diagnostic markers of kidney cancer, include MCM3AP (JP Pat. Publication No. 2005-520536), KRT19 (JP Pat. Publication No. 2005-507997), SLK4 (WO2002/06339), FGF2 (Miyake, H. et al., 1996, Cancer Research, Vol. 56, p 2440-2445), MMP14 (Kitagawa, Y., 1999, Journal of Urology, Vol. 162, p 905-909), and ERBB2 (Freeman, M. R., 1989, Cancer Research, Vol. 49, p 6221-6225). Further, International Pat. Publication Nos. WO2006/099485A2 and WO2003/046581 and U.S. Pat. Publication No. 2006/0183120A1 disclose methods of diagnosing kidney cancer based on using specific diagnostic markers.

The present invention has been completed based on using proteins specific to renal cell carcinoma as diagnostic markers therefor.

DISCLOSURE

[Technical Problem]

It is therefore an object of the present invention to provide a composition for diagnosing renal cell carcinoma.

It is another object of the present invention to provide a kit for diagnosing renal cell carcinoma.

It is a further object of the present invention to provide a method of screening a therapeutic agent for renal cell carcinoma.

It is yet another object of the present invention to provide a method of screening a substance that causes renal cell carcinoma.

[Technical Solution]

In one aspect, the present invention relates to a composition for diagnosing renal cell carcinoma.

The composition for diagnosing renal cell carcinoma includes an antibody binding specifically to nicotinamide N-methyltransferase (NNMT), L-plastin, secretagogin (SCGN), NM23A, CapG, which is an actin regulatory protein, and/or C4aANA, which is a fragment that is released from the C4 complement by proteolytic cleavage and have an anaphylatoxin part.

Nicotinamide N-methyltransferase (NNMT) is an enzyme that catalyzes the N-methylation of nicotinamide. It has rarely been known to have an association with cancer. The enzyme consists of 264 amino acids (see, SEQ ID No. 1 for the amino acid sequence thereof and SEQ ID No. 2 for the nucleotide sequence thereof), and has a molecular weight of 29.6 kDa. Two-dimensional electrophoresis analysis according to the present invention revealed that the enzyme has an isoelectric point (pI) of 5.12 and a molecular weight of 29.2 kDa. The nucleotide and amino acid sequences thereof are disclosed herein, and also can be located in the Genbank database (Gene ID: U08021.1) and the Swiss-PROT database (Swiss-PROT: P40261&U08021).

Plastins belong to a subclass of actin-binding proteins. Two major isoforms have been characterized: T-plastin and L-plastin. L-plastin (also known as LCP-1) is present predominantly in hematopoietic cells, but has also been found in diverse types of tumor cells during carcinogenesis. It has not been known if L-plastin is involved in kidney cancer. It consists of 627 amino acids (see, SEQ ID No. 3 for the amino acid sequence thereof and SEQ ID No. 4 for the nucleotide sequence thereof), and has a molecular weight of 70.8 kDa. Two-dimensional electrophoresis analysis according to the present invention revealed that L-plastin has an isoelectric point (pI) of 4.83 and a molecular weight of 67.03 kDa. The nucleotide and amino acid sequences of L-plastin are disclosed herein, and also can be located in the Genbank database (Gene ID: M22300) and the Swiss-PROT database (Swiss-PROT: P13796).

Secretagogin (SCGN) is expressed predominantly in the pancreas, yet also at low levels in other tissues. It has also been found in sera from patients having cerebral ischemia. It consists of 276 amino acids (see, SEQ ID No. 5 for the amino acid sequence thereof and SEQ ID No. 6 for the nucleotide sequence thereof), and has a molecular weight of 32.2 kDa. Two-dimensional electrophoresis analysis according to the present invention revealed that SCGN has an isoelectric point (pI) of 4.68 and a molecular weight of 32.5 kDa. A recent report showed that SCGN is differentially expressed in tumors of the human brain (APMIS, 2007 April, 115(4):319-26). The nucleotide and amino acid sequences of SCGN are disclosed herein, and also can be located in the Genbank database (Gene ID: Y16752) and the Swiss-PROT database (Swiss-PROT: 076038).

NM23 genes exhibit reduced mRNA expression levels in metastatic tumor cells. A NM23 gene encodes a polypeptide that consists of 152 amino acids (see, SEQ ID No. 7 for the amino acid sequence thereof and SEQ ID No. 8 for the nucleotide sequence thereof) which has a predicted molecular weight of 16.9 kDa. Two-dimensional electrophoresis analysis according to the present invention revealed that the

NM23A protein has a pI of 5.8 and a molecular weight of 17.3 kDa. The inventors of this application found that NM23A is highly expressed in kidney tumor tissues. The nucleotide and amino acid sequences of NM23A are disclosed herein, and also can be located in the Genbank database (Gene ID: NM_198175 & NP_937818).

The actin regulatory protein CapG reversibly blocks the barbed ends of actin filaments, and plays an important role in regulating cytoplasmic and nuclear structures. The CapG protein is overexpressed in pancreatic cancer (Gut. 2007 January, 56(1):95-106, Epub 2006 Jul. 17) and in oral squamous cell carcinoma (BMC Cancer. 2008 Feb. 1, 8:39). CapG overexpression has been recently reported to affect the motility and spread of tumor cells. The CapG protein consists of 238 amino acids (see, SEQ ID No. 9 for the amino acid sequence thereof and SEQ ID No. 10 for the nucleotide sequence thereof). Two-dimensional electrophoresis analysis according to the present invention revealed that the CapG protein has a pI of 6.3 and a molecular weight of 40.6 kDa. The nucleotide and amino acid sequences of CapG are disclosed herein, and also can be located in the Genbank database (Gene ID: U12026) and the Swiss-PROT database (Swiss-PROT: P40121).

C4aANA is an activation peptide that is released from the complement C4, mediating local inflammatory reactions in the blood, through cleavage of the complement C4 and possesses anaphylatoxin activity. Renal cell carcinoma patients show increased plasma levels of C4aANA. The C4aANA is a peptide fragment of 245 amino acids, which correspond to a sequence spanning positions from 710 to 945 of complement C4-A precursor (Swiss-PROT: POC0L4; see, SEQ ID No. 11 for the amino acid sequence thereof and SEQ ID No. 12 for the nucleotide sequence thereof). There has been no report describing that the peptide is present at elevated levels in kidney cancer and other types of cancer. The nucleotide and amino acid sequences of C4aANA are disclosed herein, and also can be located in the Swiss-PROT database (Swiss-PROT: POC0L4 & K02403).

The aforementioned proteins are referred herein to as "renal cell carcinoma markers" for convenience.

As is described in the below examples, the renal cell carcinoma marker proteins are expressed in renal cell carcinoma patients, or are expressed at higher levels than those in kidney tissues of normal individuals or in normal tissues of the kidney.

The composition for diagnosing renal cell carcinoma according to the present invention may be directly or indirectly used to identify renal cell carcinoma development and to monitor renal cell carcinoma progression and/or response to its treatment.

The present composition may include a single antibody against a single renal cell carcinoma marker, or may include a mixture of different antibodies against two or more renal cell carcinoma markers. The composition may be in any form of a freeze-dried solid or a solution such as aqueous solutions or buffers.

The composition for diagnosing renal cell carcinoma according to the present invention may be used to detect the expression of renal cell carcinoma markers described above, through being brought into contact with a biological sample and then drawing a comparison of expression levels therein with those in a normal kidney tissue or a kidney tissue from a normal individual.

When the marker expression level is higher than the normal level, a subject is diagnosed with renal cell carcinoma, wherein the normal level may be calculated from the mean value of measured expression levels of a renal cell carcinoma

marker in samples from several healthy individuals and/or samples from several individuals having a kidney cancer).

The term "biological sample" as used herein, refers to a sample that is collected from a subject who exhibits a different expression level of a renal cell carcinoma marker as described above, as compared to an expression level of a normal control sample. The expression level varies according to the development or progression of renal cell carcinoma. Examples of the biological samples include kidney tissues, cancerous kidney tissues, cells derived from such tissues, and bodily fluid samples such as whole blood, plasma and serum samples.

The term "specifically bind," as used herein, means that an antibody forms an antigen-antibody complex with an antigen protein thereof, that is, a renal cell carcinoma marker, but does not substantially form such a complex with other proteins. The term "substantially," as used herein, means that nonspecific complex formation may occur even at low levels. In other words, the term "specifically bind" can be expressed as binding determined by a specific structure of an antigen protein, that is, the antigenic determinant of the antigen, epitope.

The term "epitope", as used herein, is meant to indicate a portion of a renal cell carcinoma marker as described above that defines an antigenic determinant, i.e. which possesses antigenicity or immunogenicity. An epitope typically consists of at least ten amino acids. The epitope can be identified using any epitope analysis method known in the art, such as phage display or reverse immunogenetics.

The term "antibody", as used herein, is meant to include all forms of a molecule capable of binding specifically to a renal cell carcinoma marker according to the present invention. Thus, the antibody includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (which recognize two or more antigens or epitopes; e.g., bispecific antibodies), as well as fragments of an antibody molecule, recombinant antibodies and chemically modified antibodies, which retain an ability to specifically bind to any one of the renal cell carcinoma diagnostic markers of the present invention. Examples of antibody fragments include Fab, F(ab')₂, single chain Fv (scFv; consisting of a variable heavy (VH) chain and a variable light (VL) chain connected by an appropriate linker), Fv, and Fab/c (having one Fab and a complete Fc). The antibody fragments may be obtained by treating a whole antibody with a proteolytic enzyme, such as papain or pepsin, or by introducing a gene encoding an antibody fragment into host cells using a recombinant DNA technique as described below and expressing the gene in the host cells. The immunoglobulin isotypes of the above antibodies are not specifically limited as long as they retain the ability to bind specifically to a renal cell carcinoma diagnostic marker according to the present invention, and may be any one of IgG, IgM, IgA, IgE and IgD.

The expression levels of renal cell carcinoma markers in biological samples may be evaluated through the specific binding of the above antibodies to an antigen present in the samples. The antigen-antibody complexes may be quantitatively and/or qualitatively analyzed using various immunological analytic methods known in the art, such as enzyme immunoassay, fluorescent immunoassay, radioimmunoassay, and luminescent immunoassay. The quantitative and qualitative analysis allows the identification of renal cell carcinoma development and the monitoring of renal cell carcinoma progression and response to treatment.

The enzyme immunoassay may be performed out using peroxidase (POD), alkaline phosphatase, β -galactosidase, urease, catalase, glucose oxidase, lactate dehydrogenase, amylase, a biotin-avidin complex, or the like. The fluorescent

immunoassay may be performed out using a fluorescent substance or a fluorophore, such as fluorescein isothiocyanate, tetramethylrhodamine isothiocyanate, substituted rhodamine isothiocyanate, dichlorotriazine isothiocyanate, Alexa, or AlexaFluoro. Examples of radioisotopes useful for the radioimmunoassay include tritium, iodine (^{131}I , ^{125}I , ^{123}I , and ^{121}I), phosphorous (^{32}P), sulfur (^{35}S), and metals (e.g., ^{68}Ga , ^{67}Ga , ^{68}Ge , ^{54}Mn , ^{99}Mo , ^{99}Tc , ^{133}Xe , etc.). The luminescent immunoassay may be carried out with a luciferase system, a luminol-hydrogen peroxide-POD system, a dioxetane compound system, or the like.

When an avidin-biotin system or a streptavidin-biotin system is used, a label may be bound to an antibody according to the intended use. For the enzyme immunoassay, the conjugation of a label to an antibody may be carried out using a glutaraldehyde method, a maleimide method, a pyridyl disulfide method, or a periodic acid method. In the radioimmunoassay, a chloramine-T method or a Bolton-Hunter method may be used.

In addition to the above four methods, immunological analysis may be carried out using immunoprecipitation, turbidimetric immunoassay, Western blotting, immunostaining, and immunodiffusion. However, immunological analysis is preferably performed using the aforementioned four methods, more preferably an enzyme immunoassay, and most preferably an enzyme-linked immunosorbent assay (ELISA).

The diagnostic accuracy of an immunological analytic method for renal cell carcinoma may be assessed through receiver operating characteristic (ROC) analysis. The area under the curve (AUC) is used as a measure of accuracy. ROC analysis is a representative way to discriminate sensitivity and specificity (Zweig, M. H., and Campbell, G., Clin. Chem. 39 (1993) 561-577). The area under the receiver operating characteristic (ROC) curve (AUC) may take values between 0.5 and 1, in which 0.5 indicates that there is no difference between a patient and a normal individual and thus the patient is not discriminated with the normal individual, and 1 indicates perfect discrimination between a patient and a normal individual.

A polyclonal antibody may be prepared by immunizing an animal, such as birds (e.g., chickens, etc.) or mammals (e.g., rabbits, goats, horse, sheep, rats, etc.), with a renal cell carcinoma diagnostic marker according to the present invention. The antibody may be purified from the blood of the immunized animal using a method known in the art, such as ion-exchange chromatography and affinity chromatography.

A monoclonal antibody may be obtained by establishing a hybridoma cell line, which secretes a monoclonal antibody specific to a renal cell carcinoma diagnostic marker according to the present invention. A hybridoma cell line may be produced by immunizing an animal (e.g., mice) with a renal cell carcinoma diagnostic marker according to the present invention, extracting splenocytes from the immunized animal, fusing the splenocytes with a myeloma cell line to produce hybridoma cells from the fused cells, and identifying a hybridoma cell line producing a desired monoclonal antibody. The monoclonal antibody is then recovered from the hybridoma cells using a method known in the art.

The antibody of the present invention, as described above, is not particularly limited as long as it is able to bind specifically to the diagnostic marker of renal cell carcinoma according to the present invention, but is preferably a monoclonal antibody.

In this regard, the preparation of the monoclonal antibody of the present invention will be described below in further detail.

An immunogen, which is the renal cell carcinoma diagnostic marker of the present invention, is administered to a mammal, such as rats, mice, rabbits, monkeys and goats. The dose of the immunogen may be suitably determined taking into accounts the type of an animal to be immunized, administration route, and the like, by those skilled in the art. The dose typically ranges from about 50 to 200 μg per animal. An immunogen is typically diluted or suspended in an appropriate amount of phosphate-buffered saline (PBS) or physiological saline, emulsified with a common adjuvant, and injected subcutaneously or intraperitoneally. After the first injection, boost immunization may be performed preferably 2 to 10 times, preferably 3 to 4 times, at intervals of several days to several weeks, preferably at intervals of 1 to 4 weeks. During the immunization period, the antibody titer of sera from the immunized animal is measured, for example, using ELISA. When the antibody titer reaches a plateau, the immunogen is finally injected intravenously or intraperitoneally. Antibody-producing cells are collected two to five days after the final immunization. Examples of antibody-producing cells include splenocytes (spleen cells), lymph node cells, and peripheral blood cells. Spleen cells or lymph node cells are preferred.

After antibody-producing cells are collected, hybridoma cell lines that secrete monoclonal antibodies specific to the administered immunogen, that is, the renal cell carcinoma diagnostic marker of the present invention, are produced and identified using a technique known in the art. Hybridomas may be typically established by extracting splenocytes from the immunized animal, fusing the splenocytes with a myeloma cell line to produce hybridoma cells, and identifying a hybridoma cell line producing a monoclonal antibody binding specifically to the immunogen. Myeloma cell lines to be fused with antibody-producing cells may be commercially available cell lines derived from animals, such as mice. Preferably, myeloma cell lines are derived from an animal of the same species as an animal to be immunized. They also have drug selectivity. In other words, they cannot survive in an HAT selection medium supplemented with hypoxanthine, aminopterin and thymidine in a state of being not fused with splenocytes, but can survive in a state of being fused with splenocytes. Examples of myeloma cell lines include a P3X63 strain (ATCC TIB9), which is a BALB/c mouse-derived hypoxanthine guanine phosphoribosyl-transferase (HGPRT)-deficient cell line.

The myeloma cell lines are then fused with splenocytes that are antibody-producing cells. Cell fusion is performed in a serum-free medium for animal cell culture, such as DMEM or RPMI-1640, by mixing the antibody-producing cells with the myeloma cell lines at a proper ratio (about 1:1 to 20:1) in the presence of a cell fusion stimulator. The cell fusion stimulator, such as polyethylene glycol having an average molecular weight of 1,500 to 4,000 daltons, may be used at a concentration of about 10-80%. Also, an auxiliary agent, such as dimethylsulfoxide, may be used in combination in order to increase fusion efficiency. Further, the cell fusion may be achieved using a commercially available cell fusion device.

After the cell fusion is completed, desired hybridomas are selected. In general, the cell suspension is properly diluted, for example, in a fetal bovine serum-containing RPMI-1640 medium. Cells are then aliquotted into a microtiter plate at a density of about two million cells per well, and a selection medium is added to each well. Thereafter, the cells are cultured at 20-40° C. The medium is exchanged with the same fresh medium. When the myeloma cell line is an HGPRT-deficient strain or a thymidine kinase-deficient strain, only hybridomas of antibody-producing cells and myeloma cell lines are selectively cultured and propagated in a selection

medium supplemented with hypoxanthine, aminopterin and thymidine (HAT medium). Cells surviving for about 14 days in the selection medium are obtained as hybridomas.

Subsequently, the supernatant of the hybridoma culture is screened for the presence of a desired antibody. The screening of hybridomas may be carried out using a method known in the art. For example, an enzyme immunoassay (EIA) or ELISA, or a radioimmunoassay may be used. The fused cells are cloned, for example, using a limiting dilution method.

A cloned hybridoma is grown in an animal cell culture medium, such as 10% FBS-containing RPMI-1640, EMEM, or a serum-free medium, under general culture conditions (e.g., 37° C., 5% CO₂), for a period of about 2 to 10 days. A desired monoclonal antibody may be obtained from the supernatant of the culture.

Monoclonal antibodies may be recovered using a technique known in the art. For example, a salting-out method using ammonium sulfate, ion-exchange chromatography, affinity chromatography and gel filtration chromatography may be used, and the methods may be used singly or in combination.

As well, the monoclonal antibodies of the present invention may be produced using a recombinant DNA technique, which includes cloning an antibody gene from a hybridoma, inserting the antibody gene into a suitable vector, introducing the vector into a suitable host cell, and expressing the antibody gene in the host cell (Vandamme, A. M. et al., *Eur. J. Biochem.*, 192, 767-775, 1990).

In detail, an mRNA encoding a variable region of an antibody according to the present invention is isolated from a hybridoma producing the antibody of the present invention. The mRNA isolation is performed using a method known in the art. For example, total RNA is isolated using guanidine ultracentrifugation (Chirgwin, J. M. et al., *Biochemistry Vol 18*, 5294-5299, 1979), an AGPC method (Chomczynski, P. et al., *Anal. Biochem.*, 162, 156-159), or the like. Then, a desired mRNA is purified from the total RNA, for example, using an mRNA Purification Kit (Pharmacia). Alternatively, mRNA can be directly obtained using a QuickPrep mRNA Purification Kit (Pharmacia).

A cDNA coding for a variable (V) region of an antibody may be synthesized from the obtained mRNA using a reverse transcriptase. If desired, RACE PCR may be used for synthesis and amplification of cDNA. The cDNA thus obtained, encoding the variable region, is inserted into an expression vector that carries a DNA sequence encoding a constant (C) region of an antibody. The expression vector, as described below with respect to the production of genes of the renal cell carcinoma markers of the present invention using a recombinant DNA technique, may contain a regulatory region, such as a promoter, an enhancer, a replication origin, a polyadenylation signal, and a ribosome-binding site. The expression vector is transformed into a host cell, in which the antibody is expressed. The antibody gene may be expressed by separately inserting a DNA sequence encoding a heavy (H) chain or a light (L) chain of the antibody into an expression vector and co-transforming the vectors into a host cell, or by inserting DNA sequences encoding an H chain and an L chain into a single expression vector and transforming the vector into a host cell (WO94/11523).

The renal cell carcinoma markers of the present invention, as immunogens used to obtain the antibodies of the present invention, may be constructed using a recombinant DNA technique known in the art. Typically, a cDNA of a renal cell carcinoma marker according to the present invention is prepared, inserted into an expression vector, and transformed into a prokaryotic or eukaryotic host cell, which is cultured in

a proper medium. A desired renal cell carcinoma marker is obtained from the transformed cell or the medium of the culture. The cDNA may be constructed within the capacity of those skilled in the art based on a gene sequence searchable from nucleotide/protein database or the sequence disclosed herein.

The cDNA may be prepared through phosphoramidite-based DNA synthesis, RT-PCR, hybridization for obtaining a desired cDNA from a cDNA library, or the like. If desired, a desired cDNA sequence may be amplified, for example, using PCR.

The expression vector is commercially available from Novagen, Takara Shuzo, Qiagen, Stratagene, Promega, Roche Diagnostics, Invitrogen, Genetics Institute, and the like.

The expression vector may include, in addition to a DNA sequence encoding a renal cell carcinoma diagnostic marker according to the present invention, regulatory elements, such as a promoter, an enhancer, a polyadenylation signal, a ribosome-binding site, a replication origin, a terminator, and a selection marker. In order to facilitate protein isolation and purification, the vector may also include a purification tag peptide sequence (peptide label), such as a histidine repeat.

Host cells suitable for use in the present invention include prokaryotic cells (e.g., *E. coli* or *Bacillus subtilis*), and eukaryotic cells, such as yeast (e.g., *Saccharomyces cerevisiae*), insect cells (e.g., Sf cells), and mammalian cells (e.g., COS, CHO, BHK).

The renal cell carcinoma markers of the present invention may be purified from host cells or cultures thereof through ultrafiltration, gel filtration, ion-exchange chromatography, affinity chromatography (useful when a peptide label is bound to a polypeptide to be purified), HPLC, hydrophobic chromatography, and isoelectric chromatography. If desired, the methods are used in combination.

The production of the renal cell carcinoma markers of the present invention using a recombinant DNA technique may be achieved as disclosed herein, as well as in Sambrook et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, US (1989); Ausubel et al., *Current Protocols in Molecular Biology*, Jon Wiley & Sons, US (1993); Sambrook, J. & Russel, D., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, January 15, 2001, Vol. 1: 7.42 to 7.45, Vol. 2: 8.9 to 8.17; and the like. The above literatures are considered as a portion of this specification.

A fragment of a renal cell carcinoma marker according to the present invention may be used as an immunogen for producing an antibody against the renal cell carcinoma marker. The antibody obtained using the fragment retains also the ability to bind specifically to the renal cell carcinoma marker of the present invention.

In another aspect, the present invention relates to a kit for diagnosing renal cell carcinoma.

The diagnostic kit for renal cell carcinoma includes an antibody binding specifically to a renal cell carcinoma marker according to the present invention.

The antibody included in the diagnostic kit of the present invention may be present singly or in the form of a mixture, or may be conjugated to a solid-phase carrier or be in a free form.

The present kit may include a secondary antibody used in an immunoassay for the quantitative or qualitative detection of the expression level of the renal cell carcinoma marker (e.g., a renal cell carcinoma marker-specific antibody labeled with a fluorescein capable of detecting the expression level of

the renal cell carcinoma marker), a carrier, a washing buffer, a sample dilution buffer, an enzyme substrate, a reaction stop buffer, and the like.

The present kit may preferably include a guide book through the use of which the development or improvement of renal cell carcinoma can be determined from quantitatively or qualitatively detected expression levels of the renal cell carcinoma marker.

In a further aspect, the present invention relates to a method of screening a therapeutic agent for renal cell carcinoma.

The screening method of the present invention includes bringing a substance to be tested into contact with a renal cell carcinoma line or a renal cell carcinoma tissue, and detecting the substance to reduce expression of a renal cell carcinoma marker in the renal cell carcinoma line or the renal cell carcinoma tissue by comparing states of being contacted with and not being contacted with the test substance. The screening may be carried out using an in vivo system, for example, rats having induced renal cell carcinoma, or using an in vitro culture of a renal cell carcinoma line or a renal cell carcinoma tissue.

In a yet another aspect, the present invention relates to a method of screening for a substance that causes renal cell carcinoma.

The screening method for a substance causing renal cell carcinoma includes bringing a substance to be tested into contact with a normal kidney cell line or a normal kidney tissue, and detecting the substance to increase expression of a renal cell carcinoma marker according to the present invention in the normal kidney cell line or the normal kidney tissue by comparing states of being contacted with and not being contacted with the test substance. This screening may also be carried out either in vivo or in vitro.

In another aspect, a kidney carcinoma cell line or a cancerous kidney tissue may also be employed in the screening method of a substance causing renal cell carcinoma. In this case, the method includes bringing a substance to be tested into contact with a renal carcinoma line or a renal cell carcinoma tissue; and detecting the substance to increase expression of a renal cell carcinoma marker according to the present invention in the renal carcinoma line or the renal cell carcinoma tissue by comparing states of being contacted with and not being contacted with the test substance. This screening may also be carried out either in vivo or in vitro.

The description about the composition for diagnosing renal cell carcinoma is also applicable to the diagnostic kit for renal cell carcinoma, the method of screening a therapeutic agent for renal cell carcinoma, and the method of screening a substance causing renal cell carcinoma.

[Advantageous Effects]

In accordance with the present invention, the composition and kit of the present invention are useful for the detection of renal cell carcinoma and for purposes of arriving at a renal cell carcinoma diagnosis.

DESCRIPTION OF DRAWINGS

FIG. 1 is a 2D gel image of a normal kidney tissue from a renal cell carcinoma patient, and

FIG. 2 is a 2D gel image of a cancerous kidney tissue from a renal cell carcinoma patient.

FIG. 3 is a 2D gel image of a serum sample from a normal individual, and

FIG. 4 is a 2D gel image of a serum sample from a renal cell carcinoma patient.

FIG. 5 is a 2D gel image of a membrane fraction sample from a normal kidney tissue, and

FIG. 6 is a 2D gel image of a membrane fraction sample from cancerous kidney tissue.

FIG. 7 shows enlarged views of eight protein spots showing a significant increase in expression in cases of renal cell carcinoma in the 2D gel images of FIGS. 1, 2, 5 and 6, the eight proteins including NNMT, hNSE, L-plastin, ECGF-1, SCGN, ferritin light subunit, NM23A and CapG.

FIG. 8 shows an enlarged view of a spot of a protein showing a significant increase in expression in cases of renal cell carcinoma, namely C4aANA, in the 2D gel image of FIG. 4, wherein the protein spot is compared to the corresponding region in the gel image of FIG. 3.

FIGS. 9 to 17 show mass spectra of NNMT, L-plastin, SCGN, hNSE, ECGF-1, ferritin, NM23A, CapG and C4aANA, respectively, and the results of protein identification using the search program ProFound.

FIG. 18 shows the results of immunoblotting for NNMT expression in normal and cancerous kidney tissues.

BEST MODE FOR INVENTION

A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed as limiting the present invention.

EXAMPLE 1

Identification of Protein Markers for Renal Cell Carcinoma

1-1. Preparation of Kidney Tissue Samples from Normal Individuals and Patients

In order to investigate expression patterns of renal cell carcinoma-specific proteins, kidney tissue samples were collected from patients afflicted with renal cell carcinoma.

From 13 renal cell carcinoma patients, a total of 13 cancerous tissue samples were collected. Also, 13 normal kidney tissue samples were collected from regions adjacent to cancer.

Blood samples also were collected from renal cell carcinoma patients and normal individuals to obtain plasmas therefrom.

The normal and cancerous tissues of the kidney were homogenized and centrifuged, and membrane fractions were recovered. In brief, 200 mg of kidney cancerous tissue was homogenized in 1 ml of a protein extraction buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM benzamidin) using a homogenizer (Powergen 125, Fisher Scientific, Germany), and centrifuged at 12,000×g for 1 hr. After the supernatant was discarded, an insoluble membrane fraction was recovered.

The patients donating the tissue samples were afflicted with any one of three types of renal cell carcinoma, namely clear-cell renal cell carcinoma (RCC), papillary RCC or chromophobe RCC. Each type of renal cell carcinoma was graded according to cancer progression (size of cancer masses) into stages 1 to 4 (grade 1 (one patient)), grade 2 (two patients), grade 3 (six patients), and grade 4 (four patients).

1-2. Preparation of Protein Samples for Two-Dimensional Gel Electrophoresis

Clear-cell RCC tissues, stored at -80° C. until use, were partially cut out to obtain 200 mg of tissue using a surgical knife. 200 mg of the kidney cancerous tissue was homogenized in 0.6 ml of a protein extraction buffer for two-dimensional electrophoresis (2-DE) (7 M urea, 2 M thiourea, 4% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-pro-

panesulfonate (CHAPS), 1% (w/v) dithiothreitol (DTT), 2% (v/v) pharmalyte, 1 mM benzamidine) using a mechanical homogenizer (Powergen 125, Fisher Scientific, Germany). The tissue homogenate was agitated at a rapid speed for 1 hr so as to solubilize proteins, and centrifuged at 12,000×g for 1 hr. The resulting supernatant was recovered and used in two-dimensional electrophoresis.

Normal kidney tissues were prepared according to the same procedure as described above.

Plasmas were incubated in a 1/40 volume of a protein extraction buffer for 2-DE (7 M urea, 2 M thiourea, 4% CHAPS, 1% DTT, 2% pharmalyte, 1 mM benzamidine) with agitation at a rapid speed for 1 hr, and centrifuged at 12,000×g for 1 hr. The resulting supernatant, in which proteins were solubilized, was recovered and used in two-dimensional gel electrophoresis.

The membrane fraction samples from normal and cancerous kidney tissues were incubated in 0.2 ml of a protein extraction buffer for 2-DE (7 M urea, 2 M thiourea, 4% CHAPS, 1% DTT, 2% pharmalyte, 1 mM benzamidine) with agitation at a rapid speed for 30 min at room temperature, and centrifuged at 12,000×g. The resulting supernatant, in which proteins were solubilized, was recovered and used in two-dimensional electrophoresis.

1-3. Two-Dimensional Electrophoresis

For isoelectric focusing (IEF) as the first dimension, 0.6 ml of a reswelling solution (7 M urea, 2 M thiourea, 2% CHAPS, 1% DTT, 1% pharmalyte) was added to grooves of a DryStrip Reswelling Tray, and a 24 cm-long DryStrip ranging from pH 4 to 10 (Genomine, Inc., Pohang, Korea) was placed into the groove of the tray and allowed to be rehydrated therein for about 12-16 hrs at room temperature.

0.05 ml (0.2 mg protein) of each tissue sample, 0.08 ml (0.2 mg protein) of each plasma sample, and 0.08 ml (0.2 mg protein) of each membrane fraction sample were loaded onto the rehydrated strip. Then, IEF was carried out at 20° C. with a Multiphore II system (Amersham Biosciences) according to the user manual provided by the manufacturer. Separation was performed under voltage conditions of 150 V to 3,500 V in 3 hrs and 3,500 V for 26 hrs to reach a total of 96 kVh.

Then, the first-dimension gels were subjected to second-dimension separation (SDS-PAGE). Each gel strip was equilibrated for 10 min in a first equilibration buffer (50 mM Tris-HCl, pH 6.8, 6 M urea, 2% SDS, 30% glycerol, 1% DTT), and was subsequently further equilibrated in a second equilibration buffer (50 mM Tris-HCl, pH 6.8, 6 M urea, 2% SDS, 30% glycerol, 2.5% iodoacetamide). The equilibrated strip was positioned on top of a SDS-PAGE gel (20×24 cm, 10-16% gradient), which was run at 20° C. to reach a total of 1.7 kVh using a Hoefer DALT 2D system (Amersham Biosciences).

In order to visualize proteins, the second-dimension gel was silver-stained according to a method described in Oakley et al., *Anal. Biochem.* 1980, 105:361-363). In brief, after the second-dimension electrophoresis, the gel was incubated in a fixing solution (40% ethanol, 10% acetic acid) for 1 hr with agitation, and then incubated three times in a rehydration solution (5% ethanol, 5% acetic acid) for 30 min each time with agitation. The gel was then washed with tertiary distilled water three times for 30 min each time, and subjected to silver staining. The gel was stained through agitation in a silver staining solution (0.8% silver nitrate, 1.4% ammonia solution (25%), 0.2% 10N NaOH) for 50 min, and washed with tertiary distilled water four times for 4 min each. The washed gel was developed with a development solution (0.1% formaldehyde solution (37%), 0.01% citric acid). When a desired density of staining was achieved, the development was terminated with a rehydration solution (5% ethanol, 5% acetic

acid). The silver-stained gels were scanned using an image scanner (Duoscan T1200 scanner, AGFA, Germany), and the resulting two-dimensional gel (2D gel) images are shown in FIGS. 1 to 6.

FIG. 1 is a representative 2D gel image of a normal kidney tissue from a renal cell carcinoma patient, and FIG. 2 is a representative 2D gel image of a cancerous kidney tissue from a renal cell carcinoma patient. FIG. 3 is a representative 2D gel image of a serum sample from a normal individual, and FIG. 4 is a representative 2D gel image of a serum sample from a renal cell carcinoma patient. FIG. 5 is a representative 2D gel image of a membrane fraction sample from a normal kidney tissue, and FIG. 6 is a representative 2D gel image of a membrane fraction sample from a cancerous kidney tissue.

1-4. Comparative Analysis of Two-dimensional Images

The scanned gel images were compared with each other to assess the differential expression of proteins. The quantitative comparison of protein spots in the gel images was performed using a PDQuest software (version 7.0, BioRad). The quantity of each protein spot was normalized by total intensity of valid spots. Protein spots were selected as significant expression variations when their expression levels were 2-fold or higher compared to a control sample.

A total of 120 protein spots were selected as candidate markers, and were numbered.

1-5. In-gel Protein Digestion for Mass Spectrometry Analysis

Protein spots were enzymatically digested into small fragments using modified porcine trypsin according to a method described in Shevchenko et al., *Anal. Chem.* 1996, 68:850-858).

In brief, differentially expressed protein spots were excised from gels. Gel pieces containing the protein spots were washed in 50% acetonitrile (ACN) to remove impurities including SDS, an organic solvent and a staining reagent. For trypsin digestion, the gel pieces were then rehydrated and digested in a trypsin digestion solution (8-10 ng/μl of trypsin in trypsin digestion buffer (5% ACN, 5% NH₄HCO₃, 90% DW); 5 μl/spot) at 37° C. for 8-10 hrs. The trypsin digestion was stopped by addition of 5 μl of 0.5% trifluoroacetic acid. The trypsin-digested peptides were extracted in an aqueous solution. The solution was desalted and concentrated into a volume of 1-5 μl using a C18 ZipTip (Millipore, USA). The concentrate was mixed with the same volume of a matrix solution (α-cyano-4-hydroxycinnamic acid saturated in 50% aqueous acetonitrile), and subjected to mass spectrometry analysis.

1-6. Protein Identification Using Mass Spectrometry

Mass spectra were recorded using an Ettan MALDI-TOF mass spectrometer (Amersham Biosciences). The samples prepared in Example 1-5 were spotted onto a target plate, evaporated through radiation with a pulsed N₂ laser of 337 nm, and accelerated with a 20-kV injection pulse. Each mass spectrum for protein spots was the cumulative average of 300 laser shots. Spectra were calibrated using trypsin autodigestion peptide ion peak m/z (842.510, 2211.1046) as internal standards.

The search program ProFound, which was developed by the Rockefeller University, was used for protein identification from the mass spectra.

As a result, a total of nine proteins were identified to be significantly upregulated in renal cell carcinoma. The differentially expressed proteins included nicotinamide N-methyltransferase (NNMT), L-plastin, secretagogin (SCGN), human neuron specific enolase (hNSE), endothelial cell growth factor-1 (ECGF-1), ferritin light subunit, NM23A, actin regulatory protein (CapG), and C4aANA.

Of the identified proteins, NNMT, L-plastin, secretagoin (SCGN), CapG, NM23A and C4aANA were found to be unknown for their increased expression in renal cell carcinoma.

FIG. 7 shows enlarged views of eight protein spots showing a significant expression increase in renal cell carcinoma in the 2D gel images of FIGS. 1, 2, 5 and 6, the eight proteins including NNMT, hNSE, L-plastin, ECGF-1, SCGN, ferritin light subunit, NM23A and CapG. FIG. 8 shows an enlarged view of a spot of a protein showing a significant expression increase in renal cell carcinoma, namely C4aANA, in the 2D gel image of FIG. 4, wherein the protein spot is compared to the corresponding region in the gel image of FIG. 3.

FIGS. 9 to 17 show mass spectra of NNMT, L-plastin, SCGN, hNSE, ECGF-1, ferritin, NM23A, CapG and C4aANA, respectively, and the results of protein identification using the search program ProFound.

The test results were obtained using clear-cell RCC kidney tissues. However, when the inventors of this application tested tissue samples from other types of renal cell carcinoma (papillary RCC and chromophobe RCC) according to the same procedure as described above, the above seven proteins exhibited increased expression in cancerous kidney tissues albeit it a small one, compared to normal kidney tissues.

EXAMPLE 2

Evaluation of Differential Expression of NNMT Between Normal and Cancerous Kidney Tissues Using Western Blotting

Among the proteins identified to be upregulated in renal cell carcinoma, NNMT was assessed for its differential expression between normal and cancerous kidney tissues using Western blotting.

2-1. Preparation of a Recombinant NNMT Antigen

In order to clone an NNMT gene into pBAD/Myc-His A, which is a vector of protein large expression, PCR was carried out using a forward primer having a XhoI site (5'-CTC GAG AGA ATC AGG CTT CAC CTC CAA GGA-3') and a reverse primer having a HindIII site (5'-AAG CTT CAG GGG TCT GCT CAG CTT CCT C-3').

The amplified NNMT gene was cloned into a pBAD/Myc-His A vector, and transformed into *E. coli* (BL21) for large expression of NNMT. An *E. coli* clone was identified to carry a recombinant NNMT gene fused to a C-terminal 6 histidine tag of the pBAD/Myc-His A vector. The clone was grown in a Luria-bertani broth medium supplemented with 100 mg/L ampicillin at 37° C. with agitation. When OD₆₀₀ reached 0.5, a 20% arabinose solution was added to the medium at a final concentration of 0.2-0.0002%, and cells were further grown for 3 hrs in order to induce NNMT overexpression. The culture was centrifuged at 8,000 rpm for 15 min. The cell pellet was recovered and stored at -70° C. until protein purification.

2-2. NNMT Purification

The *E. coli* cells, in which the NNMT protein was overexpressed, were suspended in a six volume of a buffer (50 mM Tris-HCl, pH 7.5, 5 mM imidazol), and disrupted through sonication at a duty cycle of 50% four times for 2 min each. The cell lysate was subjected to high-speed centrifugation in order to remove insoluble materials. The supernatant was passed through a Ni-NTA column equilibrated with a buffer (50 mM Tris-HCl, pH 7.5, 5 mM imidazol), and the column was washed with a ten-fold volume of the same buffer. The column was then eluted with 100 mM imidazol. The eluate was dialyzed in a buffer containing 150 mM NaCl.

2-3. Antibody Production and Purification Immunization was performed using the purified NNMT protein in order to prepare an antibody against NNMT. The NNMT protein (0.1 mg/ml) was mixed with a fresh incomplete adjuvant at a 1:1 ratio, and the resulting suspension was injected intraperitoneally into a rabbit. One week after the primary immunization, the immunogen was injected again. Two weeks after the second immunization, a final immunization was carried out through subcutaneous injection of a fresh complete adjuvant. A blood sample was collected the immunized rabbit. The blood was allowed to clot in order to remove blood cells, and the remaining serum, containing antibodies, was recovered.

The antibody molecules were isolated as follows. A protein A column was equilibrated with a buffer (50 mM Tris-HCl, pH 7.0), and the serum sample was diluted in a five volume of the same buffer. The diluted serum was then loaded to the equilibrated column. After the column was washed with a five volume of the same buffer, it was eluted with an elution buffer (Glycin-HCl, pH 3.0). The eluate was neutralized with a neutralization buffer (Tris-HCl, pH 8.8). The eluted antibody was dialyzed in a buffer (50 mM phosphate, pH 7.4), and stored at -20° C. until use.

2-4. Western Blotting for Detecting NNMT Expression

Western blotting was carried out in order to detect the NNMT protein in renal cell carcinoma and to assess the expression level of the protein.

Protein samples (2 mg/ml) from normal and cancerous kidney tissues were diluted in a 4× sample buffer, and 10 µl of each dilute was loaded onto a 12% SDS-PAGE gel. The gel was developed at 110V. The proteins separated on the gel were electrically transferred onto a PVDF membrane. After the blot was blocked in 5% skimmed milk/PBST (0.05% Tween 20), it was primarily incubated in biotinylated anti-NNMT IgG in 5% skim milk/PBST (diluted in 1:10,000) and then probed with streptavidin-HRP (diluted in 1:10,000). The blot was developed using an ECL reagent.

The results are shown in FIG. 18.

EXAMPLE 3

Evaluation of the Potential of the Identified Proteins as Diagnostic Markers

The expression levels of NNMT in samples from fourteen renal cell carcinoma patients and fifteen normal individuals were assessed to determine whether the NNMT protein has potential as a diagnostic marker for renal cell carcinoma. The diagnostic accuracy was assessed through receiver operating characteristic (ROC) analysis. ROC analysis of renal cell carcinoma patients showed good results, a sensitivity of 92.3 and a specificity of 93.7. ROC analysis using a combination of NNMT and one or more selected from L-plastin, SCGN, hNSE, ECGF-1 and ferritin showed higher accuracy than the single use of NNMT. These results indicated that the identified proteins are useful as diagnostic markers of renal cell carcinoma.

EXAMPLE 4

Detection of NNMT in Plasma Using ELISA

An anti-NNMT antibody was adjusted to a final concentration of 0.1 mg/ml in 50 mM ammonium bicarbonate (pH 9.6). 10 µl (10 µg) of the antibody was added to each well of a plate, and the plate was incubated at 4° C. overnight to immobilize the antibody. The plate was washed with 150 µl of a washing buffer (PBST, 10 mM sodium phosphate, pH 7.4,

0.9% NaCl, 0.05% Tween 20) three times, and incubated in 200 μ l of a blocking buffer (0.1% casein, 20 mM sodium phosphate, pH 7.4, 0.9% NaCl) to block the space between antibody molecules. 10 μ l of each serum sample from patients and normal individuals was diluted in 90 μ l of a reaction buffer (PEST, 0.1% casein), added to each well, and incubated for 2 hrs to allow antigen-antibody complex formation. Then, the plate was washed with 150 μ l of the washing buffer three times, incubated for 1 hr in 100 μ l of a biotin-conjugated antibody (biotin-rabbit anti-h6-NNMT IgG (1 mg/ml), diluted in 1:2,000 in the reaction buffer), and then washed with 150 μ l of the washing buffer three times. For development, 100 μ l of a 1:10,000 dilution of Stratavidin-HRP (1 mg/ml) was added to each well, and the reaction was allowed to occur for 1 hr. After the plate was washed with 150 μ l of the washing buffer five times, 100 μ l of a TMB solution (Sigma, USA) was added to each well and incubated for 8-10 min. The color reaction was stopped by adding 50 μ l of 0.5 N sulfuric

acid to each well. Absorbance was measured at 450 nm using an ELISA Reader (Molecular Dynamics, USA).

EXAMPLE 5

Evaluation of Clinical Usefulness of NNMT Using ROC Analysis

The accuracy of a diagnostic method based on the differential expression of NNMT was assessed through ROC analysis using plasma samples from 40 normal individuals and plasma samples from a total of 41 patients afflicted with conventional RCC, papillary RCC and chromophobe RCC. ROC analysis was performed using a MedCalc program. As a result, the diagnostic method was found to have an AUC of 0.80 and thus to have high accuracy in discriminating between normal individuals and RCC patients.

[Sequence List]

Attached.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 12

<210> SEQ ID NO 1

<211> LENGTH: 264

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

Met Glu Ser Gly Phe Thr Ser Lys Asp Thr Tyr Leu Ser His Phe Asn
1 5 10 15

Pro Arg Asp Tyr Leu Glu Lys Tyr Tyr Lys Phe Gly Ser Arg His Ser
20 25 30

Ala Glu Ser Gln Ile Leu Lys His Leu Leu Lys Asn Leu Phe Lys Ile
35 40 45

Phe Cys Leu Asp Gly Val Lys Gly Asp Leu Leu Ile Asp Ile Gly Ser
50 55 60

Gly Pro Thr Ile Tyr Gln Leu Leu Ser Ala Cys Glu Ser Phe Lys Glu
65 70 75 80

Ile Val Val Thr Asp Tyr Ser Asp Gln Asn Leu Gln Glu Leu Glu Lys
85 90 95

Trp Leu Lys Lys Glu Pro Glu Ala Phe Asp Trp Ser Pro Val Val Thr
100 105 110

Tyr Val Cys Asp Leu Glu Gly Asn Arg Val Lys Gly Pro Glu Lys Glu
115 120 125

Glu Lys Leu Arg Gln Ala Val Lys Gln Val Leu Lys Cys Asp Val Thr
130 135 140

Gln Ser Gln Pro Leu Gly Ala Val Pro Leu Pro Pro Ala Asp Cys Val
145 150 155 160

Leu Ser Thr Leu Cys Leu Asp Ala Ala Cys Pro Asp Leu Pro Thr Tyr
165 170 175

Cys Arg Ala Leu Arg Asn Leu Gly Ser Leu Leu Lys Pro Gly Gly Phe
180 185 190

Leu Val Ile Met Asp Ala Leu Lys Ser Ser Tyr Tyr Met Ile Gly Glu
195 200 205

Gln Lys Phe Ser Ser Leu Pro Leu Gly Arg Glu Ala Val Glu Ala Ala
210 215 220

Val Lys Glu Ala Gly Tyr Thr Ile Glu Trp Phe Glu Val Ile Ser Gln
225 230 235 240

-continued

Ser Tyr Ser Ser Thr Met Ala Asn Asn Glu Gly Leu Phe Ser Leu Val
 245 250 255

Ala Arg Lys Leu Ser Arg Pro Leu
 260

<210> SEQ ID NO 2
 <211> LENGTH: 952
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

tgaactctgg atgctgttag cctgagactc aggaagacaa cttctgcagg gtcactccct 60
 ggcttctgga ggaagagaa ggagggcagt gctccagtgg tacagaagtg agacataatg 120
 gaatcaggct tcacctccaa ggacacctat ctaagccatt ttaaccctcg ggattaccta 180
 gaaaaatatt acaagtttgg ttctagggac tctgcagaaa gccagattct taagcacctt 240
 ctgaaaaatc ttttcaagat attctgccta gacgggtgtga agggagacct gctgattgac 300
 atcggctctg gccccactat ctatcagctc ctctctgctt gtgaatcctt taaggagatc 360
 gtcgtcactg actactcaga ccagaacctg caggagctgg agaagtggct gaagaaagag 420
 ccagaggcct ttgactggtc ccagtggtg acctatgtgt gtgatcttga agggaacaga 480
 gtcaagggtc cagagaagga ggagaagttg agacaggcgg tcaagcaggt gctgaagtgt 540
 gatgtgactc agagccagcc actggggggc gtcccttac ccccggtga ctgcgtgctc 600
 agcacactgt gtctggatgc cgctgcccc gacctcccca cctactgcag ggcgctcagg 660
 aacctcgga gctactgaa gccagggggc ttcttggtga tcatggatgc gctcaagagc 720
 agctactaca tgattggtga gcagaagttc tccagcctcc ccctgggccc ggaggcagta 780
 gaggtgctg tgaagaggc tggctacaca atcgaatggt ttgaggtgat ctgcgaaagt 840
 tattcttcca ccatggccaa caacgaagga cttttctccc tggtgccgag gaagctgagc 900
 agaccctgt gatgcctgtg acctcaatta aagcaattcc tttgacctgt ca 952

<210> SEQ ID NO 3
 <211> LENGTH: 627
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

Met Ala Arg Gly Ser Val Ser Asp Glu Glu Met Met Glu Leu Arg Glu
 1 5 10 15
 Ala Phe Ala Lys Val Asp Thr Asp Gly Asn Gly Tyr Ile Ser Phe Asn
 20 25 30
 Glu Leu Asn Asp Leu Phe Lys Ala Ala Cys Leu Pro Leu Pro Gly Tyr
 35 40 45
 Arg Val Arg Glu Ile Thr Glu Asn Leu Met Ala Thr Gly Asp Leu Asp
 50 55 60
 Gln Asp Gly Arg Ile Ser Phe Asp Glu Phe Ile Lys Ile Phe His Gly
 65 70 75 80
 Leu Lys Ser Thr Asp Val Ala Lys Thr Phe Arg Lys Ala Ile Asn Lys
 85 90 95
 Lys Glu Gly Ile Cys Ala Ile Gly Gly Thr Ser Glu Gln Ser Ser Val
 100 105 110
 Gly Thr Gln His Ser Tyr Ser Glu Glu Glu Lys Tyr Ala Phe Val Asn
 115 120 125
 Trp Ile Asn Lys Ala Leu Glu Asn Asp Pro Asp Cys Arg His Val Ile

-continued

130	135	140
Pro Met Asn Pro Asn Thr Asn Asp Leu Phe Asn Ala Val Gly Asp Gly 145 150 155 160		
Ile Val Leu Cys Lys Met Ile Asn Leu Ser Val Pro Asp Thr Ile Asp 165 170 175		
Glu Arg Thr Ile Asn Lys Lys Lys Leu Thr Pro Phe Thr Ile Gln Glu 180 185 190		
Asn Leu Asn Leu Ala Leu Asn Ser Ala Ser Ala Ile Gly Cys His Val 195 200 205		
Val Asn Ile Gly Ala Glu Asp Leu Lys Glu Gly Lys Pro Tyr Leu Val 210 215 220		
Leu Gly Leu Leu Trp Gln Val Ile Lys Ile Gly Leu Phe Ala Asp Ile 225 230 235 240		
Glu Leu Ser Arg Asn Glu Ala Leu Ile Ala Leu Leu Arg Glu Gly Glu 245 250 255		
Ser Leu Glu Asp Leu Met Lys Leu Ser Pro Glu Glu Leu Leu Leu Arg 260 265 270		
Trp Ala Asn Tyr His Leu Glu Asn Ala Gly Cys Asn Lys Ile Gly Asn 275 280 285		
Phe Ser Thr Asp Ile Lys Asp Ser Lys Ala Tyr Tyr His Leu Leu Glu 290 295 300		
Gln Val Ala Pro Lys Gly Asp Glu Glu Gly Val Pro Ala Val Val Ile 305 310 315 320		
Asp Met Ser Gly Leu Arg Glu Lys Asp Asp Ile Gln Arg Ala Glu Cys 325 330 335		
Met Leu Gln Gln Ala Glu Arg Leu Gly Cys Arg Gln Phe Val Thr Ala 340 345 350		
Thr Asp Val Val Arg Gly Asn Pro Lys Leu Asn Leu Ala Phe Ile Ala 355 360 365		
Asn Leu Phe Asn Arg Tyr Pro Ala Leu His Lys Pro Glu Asn Gln Asp 370 375 380		
Ile Asp Trp Gly Ala Leu Glu Gly Glu Thr Arg Glu Glu Arg Thr Phe 385 390 395 400		
Arg Asn Trp Met Asn Ser Leu Gly Val Asn Pro Arg Val Asn His Leu 405 410 415		
Tyr Ser Asp Leu Ser Asp Ala Leu Val Ile Phe Gln Leu Tyr Glu Lys 420 425 430		
Ile Lys Val Pro Val Asp Trp Asn Arg Val Asn Lys Pro Pro Tyr Pro 435 440 445		
Lys Leu Gly Gly Asn Met Lys Lys Leu Glu Asn Cys Asn Tyr Ala Val 450 455 460		
Glu Leu Gly Lys Asn Gln Ala Lys Phe Ser Leu Val Gly Ile Gly Gly 465 470 475 480		
Gln Asp Leu Asn Glu Gly Asn Arg Thr Leu Thr Leu Ala Leu Ile Trp 485 490 495		
Gln Leu Met Arg Arg Tyr Thr Leu Asn Ile Leu Glu Glu Ile Gly Gly 500 505 510		
Gly Gln Lys Val Asn Asp Asp Ile Ile Val Asn Trp Val Asn Glu Thr 515 520 525		
Leu Arg Glu Ala Glu Lys Ser Ser Ser Ile Ser Ser Phe Lys Asp Pro 530 535 540		
Lys Ile Ser Thr Ser Leu Pro Val Leu Asp Leu Ile Asp Ala Ile Gln 545 550 555 560		

-continued

Pro	Gly	Ser	Ile	Asn	Tyr	Asp	Leu	Leu	Lys	Thr	Glu	Asn	Leu	Asn	Asp
				565					570					575	
Asp	Glu	Lys	Leu	Asn	Asn	Ala	Lys	Tyr	Ala	Ile	Ser	Met	Ala	Arg	Lys
			580					585					590		
Ile	Gly	Ala	Arg	Val	Tyr	Ala	Leu	Pro	Glu	Asp	Leu	Val	Glu	Val	Asn
		595					600					605			
Pro	Lys	Met	Val	Met	Thr	Val	Phe	Ala	Cys	Leu	Met	Gly	Lys	Gly	Met
	610					615					620				
Lys	Arg	Val													
625															

<210> SEQ ID NO 4
 <211> LENGTH: 1713
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

 <400> SEQUENCE: 4

atggctacag	gtgatctgga	ccaagatgga	aggatcagct	ttgatgagtt	tatcaagatt	60
ttccatggcc	taaaaagcac	agatgttgcc	aagaccttta	gaaaagcaat	caataagaag	120
gaagggattt	gtgcaatcgg	tggtacttca	gagcagtcta	gcgttgccac	ccaacactcc	180
tattcagagg	aagaaaagta	tgcctttgtc	aactggataa	acaagccct	ggaaaatgat	240
cctgattgtc	ggcatgtcat	cccaatgaac	ccaaacacga	atgatctctt	taatgctgtt	300
ggagatggca	ttgtcctttg	taaaatgata	aacctgtcag	tgccagacac	aattgatgaa	360
agaacaatca	acaaaaagaa	gctaaccctt	ttcaccattc	aggaaaatct	gaacttggct	420
ctgaactctg	cctcagccat	cgggtgccat	gtggtcaaca	taggggctga	ggacctgaag	480
gaggggaagc	cttatcttgt	cctgggactt	ctgtggcaag	tcatacaagat	tgggttgttt	540
gctgacattg	aactcagcag	aaatgaagct	ctgattgtct	ttttgagaga	aggtgagagc	600
ctggaggatt	tgaatgaaat	ctccctgaa	gagctcttgc	tgagggtggc	taattaccac	660
ctggaaaatg	caggctgcaa	caaaattggc	aacttcagta	ctgacatcaa	ggactcaaaa	720
gcttattacc	acctgcttga	gcagggtggc	ccaaaaggag	atgaagaagg	tgttctgct	780
gttggtattg	acatgtcagg	actgcgggag	aaggatgaca	tccagagggc	agaatgcatg	840
ctgcagcagg	cggagaggct	gggtgcctgg	cagtttgtca	cagccacaga	tgttgtccga	900
gggaacccca	agtgaaactt	ggcttttatt	gccaacctct	ttaacagata	ccctgccctg	960
cacaaaccag	agaaccagga	cattgactgg	ggggctcttg	aaggtgagac	gagagaagag	1020
cggacattta	ggaactggat	gaactccctg	ggtgttaacc	ctcgagtcaa	tcatttgtac	1080
agtgacttat	cagatgccct	ggatcatctc	cagctctatg	aaaagatcaa	agttcctgtt	1140
gactggaaca	gagtaacaaa	accgccatac	ccaaaactgg	gaggcaatat	gaagaagctt	1200
gagaattgta	actacgcggg	agaattgggg	aagaatcaag	cgaagttctc	cctggttggc	1260
atcgggtggc	aagatctcaa	tgaaggaaac	cgcactctca	cactggcctt	gatttggcag	1320
ctaatagaga	ggtatacact	gaatatccct	gaagaaattg	gtggtggcca	gaaggtcaat	1380
gatgacatta	ttgtcaactg	ggtgaatgaa	acattgaggg	aagcagagaa	aagttcatcc	1440
atctctagtt	tcaaggacct	gaagattagt	acaagtctgc	ctgttctgga	cctcatcgat	1500
gccatccaac	caggttccat	taactatgac	cttctgaaga	cagaaaatct	gaatgatgat	1560
gagaaactca	acaatgcaaa	atatgccatc	tctatggccc	gaaaaattgg	agcaagagtg	1620
tatgccctgc	cagaagacct	ggttgaagtg	aacccccaaa	tggtcatgac	cgtgtttgcc	1680
tgctcatggt	ggaaggaat	gaagagggtg	tga			1713

-continued

<210> SEQ ID NO 5
 <211> LENGTH: 276
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

```

Met Asp Ser Ser Arg Glu Pro Thr Leu Gly Arg Leu Asp Ala Ala Gly
 1          5          10          15
Phe Trp Gln Val Trp Gln Arg Phe Asp Ala Asp Glu Lys Gly Tyr Ile
          20          25          30
Glu Glu Lys Glu Leu Asp Ala Phe Phe Leu His Met Leu Met Lys Leu
          35          40          45
Gly Thr Asp Asp Thr Val Met Lys Ala Asn Leu His Lys Val Lys Gln
          50          55          60
Gln Phe Met Thr Thr Gln Asp Ala Ser Lys Asp Gly Arg Ile Arg Met
          65          70          75          80
Lys Glu Leu Ala Gly Met Phe Leu Ser Glu Asp Glu Asn Phe Leu Leu
          85          90          95
Leu Phe Arg Arg Glu Asn Pro Leu Asp Ser Ser Val Glu Phe Met Gln
          100          105          110
Ile Trp Arg Lys Tyr Asp Ala Asp Ser Ser Gly Phe Ile Ser Ala Ala
          115          120          125
Glu Leu Arg Asn Phe Leu Arg Asp Leu Phe Leu His His Lys Lys Ala
          130          135          140
Ile Ser Glu Ala Lys Leu Glu Glu Tyr Thr Gly Thr Met Met Lys Ile
          145          150          155          160
Phe Asp Arg Asn Lys Asp Gly Arg Leu Asp Leu Asn Asp Leu Ala Arg
          165          170          175
Ile Leu Ala Leu Gln Glu Asn Phe Leu Leu Gln Phe Lys Met Asp Ala
          180          185          190
Cys Ser Thr Glu Glu Arg Lys Arg Asp Phe Glu Lys Ile Phe Ala Tyr
          195          200          205
Tyr Asp Val Ser Lys Thr Gly Ala Leu Glu Gly Pro Glu Val Asp Gly
          210          215          220
Phe Val Lys Asp Met Met Glu Leu Val Gln Pro Ser Ile Ser Gly Val
          225          230          235          240
Asp Leu Asp Lys Phe Arg Glu Ile Leu Leu Arg His Cys Asp Val Asn
          245          250          255
Lys Asp Gly Lys Ile Gln Lys Ser Glu Leu Ala Leu Cys Leu Gly Leu
          260          265          270
Lys Ile Asn Pro
          275

```

<210> SEQ ID NO 6
 <211> LENGTH: 1437
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

```

cggcagcagc gctcgcgtcc tccccagcaa cagttactca aagctaataca gatagegaaa      60
gaagcaggag agcaagtcaa gaaatacggg gaaggagtcc ttcccaaagt tgtctaggtc      120
cttcgcgcgc ggtgcctggt cttcgtcgtc aacaccatgg acagctcccg ggaaccgact      180
ctggggcgct tggacgccgc tggcttctgg caggtctggc ggcgctttga tgcggatgaa      240
aaaggttaca tagaagagaa ggaactcgat gctttcttcc tccacatggt gatgaaactg      300

```

-continued

```

ggtactgatg acacggtcac gaaagcaaat ttgcacaagg tgaacacagca gtttatgact 360
acccaagatg cctctaaga tggtcgcatt cggatgaaag agcttgctgg tatgttctta 420
tctgaggatg aaaactttct tctgctcttt cgccgggaaa acccactgga cagcagcgtg 480
gagtttatgc agatttggcg caaatatgac gctgacagca gtggctttat atcagctgct 540
gagctccgca acttctctcg agacctcttt cttcaccaca aaaaggccat ttctgaggct 600
aaactggaag aatacactgg caccatgatg aagatttttg acagaaataa agatggtcgg 660
ttggatctaa atgacttagc aaggattctg gctcttcagg aaaacttctt tctccaattt 720
aaaatggatg cttgttctac tgaagaaagg aaaagggact ttgagaaaat ctttgectac 780
tatgatgta gtaaacagag agccctggaa ggcccagaag tggatgggtt tgtcaaagac 840
atgatggagc ttgtccagcc cagcatcagc ggggtggacc ttgataagtt ccgcgagatt 900
ctcctgcgtc actgcgacgt gaacaaggat ggaaaaatc agaagtctga gctggctttg 960
tgtcttgggc tgaatacaa cccataatcc cagactgctt tgccttttgc tcttactatg 1020
tttctgtgat cttgctggtg gaattgtatc tgtgcattga tgttgggaac acagtgggca 1080
aactcacaaa tgggtgtgta ttcttgggca agaagaggga cgctaggggc ttccttccac 1140
cggcgtgatc tatccctgtc tcaactgaaag ccctgtgta gtgtctgtgt tgttttccct 1200
tgaccctggg ctttctctat ctcctcaga ctcagctccc ctgttagatg gctctgcctg 1260
tccttcccca gtccaccagg gtggggggga caggggcagc tgagtgcatt cattttgtgc 1320
ttttgtgtg ggctttctgc ttagtctgaa aggtgtgtgg cattcatggc aatcctgtaa 1380
cttcaacata gatttttttt gtgtgtgtgg aaataaatct gcaattggaa acaaccg 1437

```

<210> SEQ ID NO 7

<211> LENGTH: 177

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

```

Met Val Leu Leu Ser Thr Leu Gly Ile Val Phe Gln Gly Glu Gly Pro
1           5           10          15
Pro Ile Ser Ser Cys Asp Thr Gly Thr Met Ala Asn Cys Glu Arg Thr
20          25          30
Phe Ile Ala Ile Lys Pro Asp Gly Val Gln Arg Gly Leu Val Gly Glu
35          40          45
Ile Ile Lys Arg Phe Glu Gln Lys Gly Phe Arg Leu Val Gly Leu Lys
50          55          60
Phe Met Gln Ala Ser Glu Asp Leu Leu Lys Glu His Tyr Val Asp Leu
65          70          75          80
Lys Asp Arg Pro Phe Phe Ala Gly Leu Val Lys Tyr Met His Ser Gly
85          90          95
Pro Val Val Ala Met Val Trp Glu Gly Leu Asn Val Val Lys Thr Gly
100         105         110
Arg Val Met Leu Gly Glu Thr Asn Pro Ala Asp Ser Lys Pro Gly Thr
115         120         125
Ile Arg Gly Asp Phe Cys Ile Gln Val Gly Arg Asn Ile Ile His Gly
130         135         140
Ser Asp Ser Val Glu Ser Ala Glu Lys Glu Ile Gly Leu Trp Phe His
145         150         155         160
Pro Glu Glu Leu Val Asp Tyr Thr Ser Cys Ala Gln Asn Trp Ile Tyr
165         170         175

```

-continued

Glu

<210> SEQ ID NO 8
 <211> LENGTH: 1031
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

```
gcagaagcgt tccgtgctgt caagtgtctg gaaccacgtg ggtcccgggc gcgtttcggg    60
tgctggcggc tgcagccgga gttcaaacct aagcagctgg aagggccctg tggctaggta    120
ccatagagtc tctacacagg actaagtcag cctggtgtgc aggggaggca gacacacaaa    180
cagaaaattg gactacagtg ctaagatgct gtaagaagag gttaactaaa ggacaggaag    240
atggggccaa gagatggtgc tactgtctac tttagggatc gtctttcaag gcgagggggc    300
tcctatctca agctgtgata caggaacctt ggccaactgt gacggtacct tcattgcat    360
caaaccagat ggggtccagg ggggtcttgt gggagagatt atcaagcgtt ttgagcagaa    420
aggattccgc cttgttggtc tgaaattcat gcaagcttcc gaagatcttc tcaaggaaca    480
ctacgttgac ctgaaggacc gtccattctt tgccggcctg gtgaaatata tgcactcagg    540
gccggtagtt gccatggtct gggagggggt gaatgtggtg aagacggggc gagtcatgct    600
cggggagacc aacctgcag actccaagcc tgggaccatc cgtggagact tctgcataca    660
agttggcagg aacattatac atggcagtga ttctgtggag agtgacagaga aggagatcgg    720
cttgtggttt caccctgagg aactggtaga ttacacgagc tgtgtctaga actggatcta    780
tgaatgacag gagggcagac cacattgctt ttcacatcca tttccctccc tteccatggg    840
cagaggacca ggctgttaga aatctagtta ttacaggaa cttcatcata atttgagggg    900
aagctcttgg agctgtgagt tctccctgta cagtgttacc atccccgacc atctgattaa    960
aatgtctctc ccagcatag gattcattga gttggttact tcatattgtt gcattgcttt   1020
tttttccttc t                                     1031
```

<210> SEQ ID NO 9
 <211> LENGTH: 348
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

```
Met Tyr Thr Ala Ile Pro Gln Ser Gly Ser Pro Phe Pro Gly Ser Val
1      5      10      15
Gln Asp Pro Gly Leu His Val Trp Arg Val Glu Lys Leu Lys Pro Val
20     25     30
Pro Val Ala Gln Glu Asn Gln Gly Val Phe Phe Ser Gly Asp Ser Tyr
35     40     45
Leu Val Leu His Asn Gly Pro Glu Glu Val Ser His Leu His Leu Trp
50     55     60
Ile Gly Gln Gln Ser Ser Arg Asp Glu Gln Gly Ala Cys Ala Val Leu
65     70     75     80
Ala Val His Leu Asn Thr Leu Leu Gly Glu Arg Pro Val Gln His Arg
85     90     95
Glu Val Gln Gly Asn Glu Ser Asp Leu Phe Met Ser Tyr Phe Pro Arg
100    105    110
Gly Leu Lys Tyr Gln Glu Gly Gly Val Glu Ser Ala Phe His Lys Thr
115    120    125
Ser Thr Gly Ala Pro Ala Ala Ile Lys Lys Leu Tyr Gln Val Lys Gly
130    135    140
```

-continued

Lys Lys Asn Ile Arg Ala Thr Glu Arg Ala Leu Asn Trp Asp Ser Phe
 145 150 155 160
 Asn Thr Gly Asp Cys Phe Ile Leu Asp Leu Gly Gln Asn Ile Phe Ala
 165 170 175
 Trp Cys Gly Gly Lys Ser Asn Ile Leu Glu Arg Asn Lys Ala Arg Asp
 180 185 190
 Leu Ala Leu Ala Ile Arg Asp Ser Glu Arg Gln Gly Lys Ala Gln Val
 195 200 205
 Glu Ile Val Thr Asp Gly Glu Glu Pro Ala Glu Met Ile Gln Val Leu
 210 215 220
 Gly Pro Lys Pro Ala Leu Lys Glu Gly Asn Pro Glu Glu Asp Leu Thr
 225 230 235 240
 Ala Asp Lys Ala Asn Ala Gln Ala Ala Ala Leu Tyr Lys Val Ser Asp
 245 250 255
 Ala Thr Gly Gln Met Asn Leu Thr Lys Val Ala Asp Ser Ser Pro Phe
 260 265 270
 Ala Leu Glu Leu Leu Ile Ser Asp Asp Cys Phe Val Leu Asp Asn Gly
 275 280 285
 Leu Cys Gly Lys Ile Tyr Ile Trp Lys Gly Arg Lys Ala Asn Glu Lys
 290 295 300
 Glu Arg Gln Ala Ala Leu Gln Val Ala Glu Gly Phe Ile Ser Arg Met
 305 310 315 320
 Gln Tyr Ala Pro Asn Thr Gln Val Glu Ile Leu Pro Gln Gly Arg Glu
 325 330 335
 Ser Pro Ile Phe Lys Gln Phe Phe Lys Asp Trp Lys
 340 345

<210> SEQ ID NO 10

<211> LENGTH: 944

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

atctgaagac agcatgtaca cagccattcc ccagaggtaa gctgcatgcc ccatctcctt 60
 tcacaacttc cctttcttta cctccaagcg ctgcccctcc ccaactgctct ccgctgccc 120
 agggctgtgc ttgggcaagt gggccaggc tgctgtcaac cctctctctt ctgcagtg 180
 ctctccattc ccaggctcag tgcaggatcc aggcctgcat gtgtggcggg tggagaagct 240
 gaagccgggtg cctgtggcgc aagagaacca gggcgtcttc ttctcggggg actcctacct 300
 agtgctgcac aatggcccag aagagggttc ccatctgcac ctgtggatag gtaaggggat 360
 ctggatgggg gaaggttggg ccaggaagg ggaggagggg ggctggtatg gatcacaagc 420
 cttgccctgc cctctccac ttgtccagg ccagcagtc tcccgggatg agcagggggc 480
 ctgtgccgtg ctggctgtgc acctcaacac gctgctggga gagcggcctg tgcagcaccg 540
 cgagggtcag ggcaatgagt ctgacctctt catgagctac ttcccacggg gcctcaagta 600
 ccaggtcaga gccacctct aggcaccccc accctgcttc tggtggttc tcacctgca 660
 gaagacccgg gtgcctttgg agccgggtcc ccacctttct gccgtcttc cagtgggatg 720
 ggggtgcagag ggctctgggt ctctgtcag tccactcaga tgggcccgtct gggctgcagg 780
 aaggtggtgt ggagtcagca ttccacaaga cctccacagg agccccagct gccatcaaga 840
 aactctacca ggtgaagggg aagaagaaca tccgtgccac cgagcgggca ctgaactggg 900
 acagcttcaa cactggggac tgcttcatcc tggacctggg ccag 944

-continued

```

<210> SEQ ID NO 11
<211> LENGTH: 1744
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

Met Arg Leu Leu Trp Gly Leu Ile Trp Ala Ser Ser Phe Phe Thr Leu
1          5          10          15
Ser Leu Gln Lys Pro Arg Leu Leu Leu Phe Ser Pro Ser Val Val His
          20          25          30
Leu Gly Val Pro Leu Ser Val Gly Val Gln Leu Gln Asp Val Pro Arg
          35          40          45
Gly Gln Val Val Lys Gly Ser Val Phe Leu Arg Asn Pro Ser Arg Asn
          50          55          60
Asn Val Pro Cys Ser Pro Lys Val Asp Phe Thr Leu Ser Ser Glu Arg
65          70          75          80
Asp Phe Ala Leu Leu Ser Leu Gln Val Pro Leu Lys Asp Ala Lys Ser
          85          90          95
Cys Gly Leu His Gln Leu Leu Arg Gly Pro Glu Val Gln Leu Val Ala
          100          105          110
His Ser Pro Trp Leu Lys Asp Ser Leu Ser Arg Thr Thr Asn Ile Gln
          115          120          125
Gly Ile Asn Leu Leu Phe Ser Ser Arg Arg Gly His Leu Phe Leu Gln
          130          135          140
Thr Asp Gln Pro Ile Tyr Asn Pro Gly Gln Arg Val Arg Tyr Arg Val
145          150          155          160
Phe Ala Leu Asp Gln Lys Met Arg Pro Ser Thr Asp Thr Ile Thr Val
          165          170          175
Met Val Glu Asn Ser His Gly Leu Arg Val Arg Lys Lys Glu Val Tyr
          180          185          190
Met Pro Ser Ser Ile Phe Gln Asp Asp Phe Val Ile Pro Asp Ile Ser
          195          200          205
Glu Pro Gly Thr Trp Lys Ile Ser Ala Arg Phe Ser Asp Gly Leu Glu
          210          215          220
Ser Asn Ser Ser Thr Gln Phe Glu Val Lys Lys Tyr Val Leu Pro Asn
225          230          235          240
Phe Glu Val Lys Ile Thr Pro Gly Lys Pro Tyr Ile Leu Thr Val Pro
          245          250          255
Gly His Leu Asp Glu Met Gln Leu Asp Ile Gln Ala Arg Tyr Ile Tyr
          260          265          270
Gly Lys Pro Val Gln Gly Val Ala Tyr Val Arg Phe Gly Leu Leu Asp
          275          280          285
Glu Asp Gly Lys Lys Thr Phe Phe Arg Gly Leu Glu Ser Gln Thr Lys
          290          295          300
Leu Val Asn Gly Gln Ser His Ile Ser Leu Ser Lys Ala Glu Phe Gln
305          310          315          320
Asp Ala Leu Glu Lys Leu Asn Met Gly Ile Thr Asp Leu Gln Gly Leu
          325          330          335
Arg Leu Tyr Val Ala Ala Ala Ile Ile Glu Ser Pro Gly Gly Glu Met
          340          345          350
Glu Glu Ala Glu Leu Thr Ser Trp Tyr Phe Val Ser Ser Pro Phe Ser
          355          360          365
Leu Asp Leu Ser Lys Thr Lys Arg His Leu Val Pro Gly Ala Pro Phe
          370          375          380

```

-continued

Leu	Leu	Gln	Ala	Leu	Val	Arg	Glu	Met	Ser	Gly	Ser	Pro	Ala	Ser	Gly	385	390	395	400
Ile	Pro	Val	Lys	Val	Ser	Ala	Thr	Val	Ser	Ser	Pro	Gly	Ser	Val	Pro	405	410	415	
Glu	Val	Gln	Asp	Ile	Gln	Gln	Asn	Thr	Asp	Gly	Ser	Gly	Gln	Val	Ser	420	425	430	
Ile	Pro	Ile	Ile	Ile	Pro	Gln	Thr	Ile	Ser	Glu	Leu	Gln	Leu	Ser	Val	435	440	445	
Ser	Ala	Gly	Ser	Pro	His	Pro	Ala	Ile	Ala	Arg	Leu	Thr	Val	Ala	Ala	450	455	460	
Pro	Pro	Ser	Gly	Gly	Pro	Gly	Phe	Leu	Ser	Ile	Glu	Arg	Pro	Asp	Ser	465	470	475	480
Arg	Pro	Pro	Arg	Val	Gly	Asp	Thr	Leu	Asn	Leu	Asn	Leu	Arg	Ala	Val	485	490	495	
Gly	Ser	Gly	Ala	Thr	Phe	Ser	His	Tyr	Tyr	Tyr	Met	Ile	Leu	Ser	Arg	500	505	510	
Gly	Gln	Ile	Val	Phe	Met	Asn	Arg	Glu	Pro	Lys	Arg	Thr	Leu	Thr	Ser	515	520	525	
Val	Ser	Val	Phe	Val	Asp	His	His	Leu	Ala	Pro	Ser	Phe	Tyr	Phe	Val	530	535	540	
Ala	Phe	Tyr	Tyr	His	Gly	Asp	His	Pro	Val	Ala	Asn	Ser	Leu	Arg	Val	545	550	555	560
Asp	Val	Gln	Ala	Gly	Ala	Cys	Glu	Gly	Lys	Leu	Glu	Leu	Ser	Val	Asp	565	570	575	
Gly	Ala	Lys	Gln	Tyr	Arg	Asn	Gly	Glu	Ser	Val	Lys	Leu	His	Leu	Glu	580	585	590	
Thr	Asp	Ser	Leu	Ala	Leu	Val	Ala	Leu	Gly	Ala	Leu	Asp	Thr	Ala	Leu	595	600	605	
Tyr	Ala	Ala	Gly	Ser	Lys	Ser	His	Lys	Pro	Leu	Asn	Met	Gly	Lys	Val	610	615	620	
Phe	Glu	Ala	Met	Asn	Ser	Tyr	Asp	Leu	Gly	Cys	Gly	Pro	Gly	Gly	Gly	625	630	635	640
Asp	Ser	Ala	Leu	Gln	Val	Phe	Gln	Ala	Ala	Gly	Leu	Ala	Phe	Ser	Asp	645	650	655	
Gly	Asp	Gln	Trp	Thr	Leu	Ser	Arg	Lys	Arg	Leu	Ser	Cys	Pro	Lys	Glu	660	665	670	
Lys	Thr	Thr	Arg	Lys	Lys	Arg	Asn	Val	Asn	Phe	Gln	Lys	Ala	Ile	Asn	675	680	685	
Glu	Lys	Leu	Gly	Gln	Tyr	Ala	Ser	Pro	Thr	Ala	Lys	Arg	Cys	Cys	Gln	690	695	700	
Asp	Gly	Val	Thr	Arg	Leu	Pro	Met	Met	Arg	Ser	Cys	Glu	Gln	Arg	Ala	705	710	715	720
Ala	Arg	Val	Gln	Gln	Pro	Asp	Cys	Arg	Glu	Pro	Phe	Leu	Ser	Cys	Cys	725	730	735	
Gln	Phe	Ala	Glu	Ser	Leu	Arg	Lys	Lys	Ser	Arg	Asp	Lys	Gly	Gln	Ala	740	745	750	
Gly	Leu	Gln	Arg	Ala	Leu	Glu	Ile	Leu	Gln	Glu	Glu	Asp	Leu	Ile	Asp	755	760	765	
Glu	Asp	Asp	Ile	Pro	Val	Arg	Ser	Phe	Phe	Pro	Glu	Asn	Trp	Leu	Trp	770	775	780	
Arg	Val	Glu	Thr	Val	Asp	Arg	Phe	Gln	Ile	Leu	Thr	Leu	Trp	Leu	Pro	785	790	795	800
Asp	Ser	Leu	Thr	Thr	Trp	Glu	Ile	His	Gly	Leu	Ser	Leu	Ser	Lys	Thr	805	810	815	

-continued

Lys Gly Leu Cys Val Ala Thr Pro Val Gln Leu Arg Val Phe Arg Glu
 820 825 830
 Phe His Leu His Leu Arg Leu Pro Met Ser Val Arg Arg Phe Glu Gln
 835 840 845
 Leu Glu Leu Arg Pro Val Leu Tyr Asn Tyr Leu Asp Lys Asn Leu Thr
 850 855 860
 Val Ser Val His Val Ser Pro Val Glu Gly Leu Cys Leu Ala Gly Gly
 865 870 875 880
 Gly Gly Leu Ala Gln Gln Val Leu Val Pro Ala Gly Ser Ala Arg Pro
 885 890 895
 Val Ala Phe Ser Val Val Pro Thr Ala Ala Ala Ala Val Ser Leu Lys
 900 905 910
 Val Val Ala Arg Gly Ser Phe Glu Phe Pro Val Gly Asp Ala Val Ser
 915 920 925
 Lys Val Leu Gln Ile Glu Lys Glu Gly Ala Ile His Arg Glu Glu Leu
 930 935 940
 Val Tyr Glu Leu Asn Pro Leu Asp His Arg Gly Arg Thr Leu Glu Ile
 945 950 955 960
 Pro Gly Asn Ser Asp Pro Asn Met Ile Pro Asp Gly Asp Phe Asn Ser
 965 970 975
 Tyr Val Arg Val Thr Ala Ser Asp Pro Leu Asp Thr Leu Gly Ser Glu
 980 985 990
 Gly Ala Leu Ser Pro Gly Gly Val Ala Ser Leu Leu Arg Leu Pro Arg
 995 1000 1005
 Gly Cys Gly Glu Gln Thr Met Ile Tyr Leu Ala Pro Thr Leu Ala
 1010 1015 1020
 Ala Ser Arg Tyr Leu Asp Lys Thr Glu Gln Trp Ser Thr Leu Pro
 1025 1030 1035
 Pro Glu Thr Lys Asp His Ala Val Asp Leu Ile Gln Lys Gly Tyr
 1040 1045 1050
 Met Arg Ile Gln Gln Phe Arg Lys Ala Asp Gly Ser Tyr Ala Ala
 1055 1060 1065
 Trp Leu Ser Arg Asp Ser Ser Thr Trp Leu Thr Ala Phe Val Leu
 1070 1075 1080
 Lys Val Leu Ser Leu Ala Gln Glu Gln Val Gly Gly Ser Pro Glu
 1085 1090 1095
 Lys Leu Gln Glu Thr Ser Asn Trp Leu Leu Ser Gln Gln Gln Ala
 1100 1105 1110
 Asp Gly Ser Phe Gln Asp Pro Cys Pro Val Leu Asp Arg Ser Met
 1115 1120 1125
 Gln Gly Gly Leu Val Gly Asn Asp Glu Thr Val Ala Leu Thr Ala
 1130 1135 1140
 Phe Val Thr Ile Ala Leu His His Gly Leu Ala Val Phe Gln Asp
 1145 1150 1155
 Glu Gly Ala Glu Pro Leu Lys Gln Arg Val Glu Ala Ser Ile Ser
 1160 1165 1170
 Lys Ala Asn Ser Phe Leu Gly Glu Lys Ala Ser Ala Gly Leu Leu
 1175 1180 1185
 Gly Ala His Ala Ala Ala Ile Thr Ala Tyr Ala Leu Ser Leu Thr
 1190 1195 1200
 Lys Ala Pro Val Asp Leu Leu Gly Val Ala His Asn Asn Leu Met
 1205 1210 1215
 Ala Met Ala Gln Glu Thr Gly Asp Asn Leu Tyr Trp Gly Ser Val

-continued

1220	1225	1230
Thr Gly Ser Gln Ser Asn Ala Val Ser Pro Thr Pro Ala Pro Arg 1235 1240 1245		
Asn Pro Ser Asp Pro Met Pro Gln Ala Pro Ala Leu Trp Ile Glu 1250 1255 1260		
Thr Thr Ala Tyr Ala Leu Leu His Leu Leu Leu His Glu Gly Lys 1265 1270 1275		
Ala Glu Met Ala Asp Gln Ala Ser Ala Trp Leu Thr Arg Gln Gly 1280 1285 1290		
Ser Phe Gln Gly Gly Phe Arg Ser Thr Gln Asp Thr Val Ile Ala 1295 1300 1305		
Leu Asp Ala Leu Ser Ala Tyr Trp Ile Ala Ser His Thr Thr Glu 1310 1315 1320		
Glu Arg Gly Leu Asn Val Thr Leu Ser Ser Thr Gly Arg Asn Gly 1325 1330 1335		
Phe Lys Ser His Ala Leu Gln Leu Asn Asn Arg Gln Ile Arg Gly 1340 1345 1350		
Leu Glu Glu Glu Leu Gln Phe Ser Leu Gly Ser Lys Ile Asn Val 1355 1360 1365		
Lys Val Gly Gly Asn Ser Lys Gly Thr Leu Lys Val Leu Arg Thr 1370 1375 1380		
Tyr Asn Val Leu Asp Met Lys Asn Thr Thr Cys Gln Asp Leu Gln 1385 1390 1395		
Ile Glu Val Thr Val Lys Gly His Val Glu Tyr Thr Met Glu Ala 1400 1405 1410		
Asn Glu Asp Tyr Glu Asp Tyr Glu Tyr Asp Glu Leu Pro Ala Lys 1415 1420 1425		
Asp Asp Pro Asp Ala Pro Leu Gln Pro Val Thr Pro Leu Gln Leu 1430 1435 1440		
Phe Glu Gly Arg Arg Asn Arg Arg Arg Arg Glu Ala Pro Lys Val 1445 1450 1455		
Val Glu Glu Gln Glu Ser Arg Val His Tyr Thr Val Cys Ile Trp 1460 1465 1470		
Arg Asn Gly Lys Val Gly Leu Ser Gly Met Ala Ile Ala Asp Val 1475 1480 1485		
Thr Leu Leu Ser Gly Phe His Ala Leu Arg Ala Asp Leu Glu Lys 1490 1495 1500		
Leu Thr Ser Leu Ser Asp Arg Tyr Val Ser His Phe Glu Thr Glu 1505 1510 1515		
Gly Pro His Val Leu Leu Tyr Phe Asp Ser Val Pro Thr Ser Arg 1520 1525 1530		
Glu Cys Val Gly Phe Glu Ala Val Gln Glu Val Pro Val Gly Leu 1535 1540 1545		
Val Gln Pro Ala Ser Ala Thr Leu Tyr Asp Tyr Tyr Asn Pro Glu 1550 1555 1560		
Arg Arg Cys Ser Val Phe Tyr Gly Ala Pro Ser Lys Ser Arg Leu 1565 1570 1575		
Leu Ala Thr Leu Cys Ser Ala Glu Val Cys Gln Cys Ala Glu Gly 1580 1585 1590		
Lys Cys Pro Arg Gln Arg Arg Ala Leu Glu Arg Gly Leu Gln Asp 1595 1600 1605		
Glu Asp Gly Tyr Arg Met Lys Phe Ala Cys Tyr Tyr Pro Arg Val 1610 1615 1620		

-continued

Glu Tyr Gly Phe Gln Val Lys Val Leu Arg Glu Asp Ser Arg Ala	
1625 1630 1635	
Ala Phe Arg Leu Phe Glu Thr Lys Ile Thr Gln Val Leu His Phe	
1640 1645 1650	
Thr Lys Asp Val Lys Ala Ala Ala Asn Gln Met Arg Asn Phe Leu	
1655 1660 1665	
Val Arg Ala Ser Cys Arg Leu Arg Leu Glu Pro Gly Lys Glu Tyr	
1670 1675 1680	
Leu Ile Met Gly Leu Asp Gly Ala Thr Tyr Asp Leu Glu Gly His	
1685 1690 1695	
Pro Gln Tyr Leu Leu Asp Ser Asn Ser Trp Ile Glu Glu Met Pro	
1700 1705 1710	
Ser Glu Arg Leu Cys Arg Ser Thr Arg Gln Arg Ala Ala Cys Ala	
1715 1720 1725	
Gln Leu Asn Asp Phe Leu Gln Glu Tyr Gly Thr Gln Gly Cys Gln	
1730 1735 1740	

Val

<210> SEQ ID NO 12

<211> LENGTH: 5406

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

gaccagatca gccccagag cagcctcatg gctggaggat ccaagagagg ttagatccgt	60
ctgtctgtct gctacatttc tcacctatc tctgcagaag cccagggtgc tctgtttctc	120
tccttctgtg gttcatctgg ggggtccctc atcggtgggg gtgcagctcc aggatgtgcc	180
ccgaggacag gtatgtaaaag gatcagtggt cctgagaaac ccattctcgtg ataattgtccc	240
ctgtctccca aagggtgact tcaccttag ctcagaaaga gacttcgcac tctcagttct	300
ccagggtgcc ttgaaagatg cgaagagctg tggcctccat caactcctca gaggcctga	360
ggtccagctg gtggcccatc cgccatgggt aaaggactct ctgtccagaa cgacaaacat	420
ccagggtatc aacctgtctc tctcctctcg cggggggcac ctctttttgc agacggacca	480
gccccattac aacctgtggt agcgggttcg gtaccgggtc tttgtctgtg atcagaagat	540
gcgcccgagc actgacacca tcacagtcac ggtggagaa cctcacggcc tccgcgtgctg	600
gaagaaggag gtgtacatgc cctcgtccat cttccaggat gactttgtga tcccagacat	660
ctcagagcca gggacctgga agatctcagc ccgattctca gatggcctgg aatccaacag	720
cagcaccagc tttgaggtga agaaatatgt ccttcccaac tttgaggtga agatcaccac	780
tggaaagccc tacatcctga cgggtgccag ccatcttgat gaaatgcagt tagacatcca	840
ggccaggtag atctatggga agccagtgca ggggggtggc tatgtgcgct ttgggtctct	900
agatgaggat ggtaagaaga cttctcttcg ggggtgggag agtcagacca agctggtgaa	960
tggacagagc cacatttccc tctcaaaggc agagttccag gacgccctgg agaagctgaa	1020
tatgggcatt actgacctcc aggggtctgc cctctacgtt gctgcagcca tcattgagtc	1080
tccaggtggg gagatggagg aggcagagct cacatcctgg tattttgtgt catctccctt	1140
ctccttggat cttagcaaga ccaagcgaca ccttgtgctt ggggccccct tctgtctgca	1200
ggccttgggc cgtgagatgt caggctcccc agcttctggc attcctgtca aagtttctgc	1260
cacggtgtct tctcctgggt ctgttctgta agcccaggac attcagcaaa acacagacgg	1320
gagcggccaa gtcagcatc caataattat cctcagacc atctcagagc tgcagctctc	1380

-continued

agtatctgca	ggctcccccac	atccagcgcg	agccaggctc	actgtggcag	ccccaccttc	1440
aggaggcccc	gggtttctgt	ctattgagcg	gccggattct	cgacctcttc	gtgttgggga	1500
cactctgaac	ctgaacttgc	gagccgtggg	cagtggggcc	accttttctc	attactacta	1560
catgatccta	tcccaggggc	agatcgtggt	catgaatcga	gagcccaaga	ggacctgac	1620
ctcggctctg	gtgtttgtgg	accatcacct	ggcacctctc	ttctactttg	tggccttcta	1680
ctaccatgga	gaccaccacg	tggccaactc	cctgcgagtg	gatgtccagg	ctggggcctg	1740
cgagggaag	ctggagctca	gcgtggacgg	tgccaagcag	taccggaacg	gggagtcctg	1800
gaagctccac	ttagaaaccg	actccctagc	cctggtggcg	ctgggagcct	tggacacagc	1860
tctgtatgct	gcaggcagca	agtcccacaa	gcccctcaac	atgggcaagg	tctttgaagc	1920
tatgaacagc	tatgacctcg	gctgtggtcc	tgggggtggg	gacagtgcct	ttcagtggtt	1980
ccaggcagcg	ggcctggcct	tttctgatgg	agaccagtgg	accttatcca	gaaagagact	2040
aagctgtccc	aaggagaaga	caaccgcgaa	aaagagaaac	gtgaacttcc	aaaaggcgat	2100
taatgagaaa	ttgggtcagt	atgcttcccc	gacagccaag	cgtgctgcc	aggatggggt	2160
gacacgtctg	cccatgatgc	gttctctcga	gcagcgggca	gcccgcgtgc	agcagccgga	2220
ctgccgggag	cccttctctg	cctgctgcca	atttgctgag	agtctgcgca	agaagagcag	2280
ggacaagggc	caggcggggc	tccaacgagc	cctggagatc	ctgcaggagg	aggacctgat	2340
tgatgaggat	gacattcccc	tgcgcagctt	cttcccagag	aactggctct	ggagagtgga	2400
aacagtggac	cgttttcaaa	tattgacact	gtggctcccc	gactctctga	ccacgtggga	2460
gatccatggc	ctgagcctgt	ccaaaaccaa	aggcctatgt	gtggccaccc	cagtcacagt	2520
ccgggtgttc	cgcgagttcc	acctgcacct	ccgcctgccc	atgtctgtcc	gccgctttga	2580
gcagctggag	ctgcggcctg	tccctctata	ctacctggat	aaaaacctga	ctgtgagcgt	2640
ccacgtgtcc	ccagtggagg	ggctgtgcct	ggctgggggc	ggagggtctg	cccagcaggt	2700
gctggtgcct	gcgggctctg	cccgccctgt	tgccttctct	gtggtgcccc	cggcagccgc	2760
cgtgtgtct	ctgaagggtg	tggctcgagg	gtccttcgaa	ttccctgtgg	gagatcggtt	2820
gtccaagggt	ctgcagattg	agaaggaagg	ggccatccat	agagaggagc	tggctctatga	2880
actcaacccc	ttggaccacc	gaggccggac	cttggaata	cctggcaact	ctgateccaa	2940
tatgatccct	gatggggact	ttaacagcta	cgtcagggtt	acagcctcag	atccattgga	3000
cactttaggc	tctgaggggg	ccttgtcacc	aggaggcgtg	gcctccctct	tgaggcttcc	3060
tcgaggctgt	ggggagcaaa	ccatgatcta	cttggctccg	aaactggctg	cttcccgtca	3120
cctggacaag	acagagcagt	ggagcacact	gcctcccag	accaaggacc	acgccgtgga	3180
tctgatccag	aaaggctaca	tgcggatcca	gcagtttcgg	aaggcggatg	gttcctatgc	3240
ggcttggttg	tcacgggaca	gcagcacctg	gtcacagcc	tttgtgtga	aggtcctgag	3300
tttggcccag	gagcaggtag	gaggctcgcc	tgagaaactg	caggagacat	ctaactggct	3360
tctgtcccag	cagcaggctg	acggctcgtt	ccaggacccc	tgtccagtgt	tagacaggag	3420
catgcagggg	ggtttgggtg	gcaatgatga	gactgtggca	ctcacagcct	ttgtgacct	3480
cgccttctcat	catgggctgg	cgtctctcca	ggatgagggt	gcagagccat	tgaagcagag	3540
agtgaagcc	tccatctcaa	aggcaaacct	atttttgggg	gagaaagcaa	gtgctgggct	3600
cctgggtgcc	cacgcagctg	ccatcacggc	ctatgccctg	tcaactgacca	aggcgcctgt	3660
ggacctgtc	ggtgtttgcc	acaacaacct	catggcaatg	gcccaggaga	ctggagataa	3720
cctgtactgg	ggctcagtc	ctggttctca	gagcaatgcc	gtgtgcacca	ccccggctcc	3780

-continued

tcgcaaccca tccgaccca tgccccaggg cccagccctg tggattgaaa ccacagccta	3840
cgcctctgtg cactctctgc ttcacgaggg caaagcagag atggcagacc aggcctcggc	3900
ctggctcacc cgtcagggca gcttccaagg gggattccgc agtacccaag acacggtgat	3960
tgccctggat gcctgtcttg cctaactggat tgccctccac accactgagg agaggggtct	4020
caatgtgact ctcagctcca caggccggaa tgggttcaag tcccacgcgc tgcagtgaa	4080
caaccgccag attcgcggcc tggaggagga gctgcagttt tccttgggca gcaagatcaa	4140
tgtgaagggt ggaggaacaa gcaaaggaac cctgaaggtc cttcgtacct acaatgtcct	4200
ggacatgaag aacacgacct gccaggacct acagatagaa gtgacagtca aagggcacgt	4260
cgagtacacg atggaagcaa acgaggacta tgagtacgat gagcttcag ccaaggatga	4320
cccagatgcc cctctgcagc ccgtgacacc cctgcagctg tttgaggggc ggaggaaccg	4380
ccgcaggagg gaggcgcccc aggtgggtgga ggagcaggag tccaggggtgc actacaccgt	4440
gtgcactctg cggaacggca aggtggggct gtctggcatg gccatcgcgg acgtcacct	4500
cctgagtgga ttccacgccc tgcgtgctga cctggagaag ctgacctccc tctctgaccg	4560
ttacgtgagt cactttgaga ccgaggggcc ccacgtcctg ctgtattttg actcggtcct	4620
cacctcccg gagtgctggt gctttgaggc tgtgcaggaa gtgccgggtg ggctggtgca	4680
gccggccagc gcaaccctgt acgactacta caaccccgag cgcagatggt ctgtgtttta	4740
cggggcacca agtaagagca gactcttggc cactctgtgt tctgctgaag tctgccagt	4800
tgctgagggg aagtgccttc gccagcgtcg cgcctggag cggggctctgc aggacgagga	4860
tggctacagg atgaagtttg cctgctacta ccccgctgtg gactacggct tccaggttaa	4920
ggttctccga gaagacagca gagtgcttt ccgcctcttt gagaccaaga taccacaagt	4980
cctgcacttc accaaggatg tcaaggccgc tgctaatacag atgcgcaact tctgggttcg	5040
agcctcctgc cgccttcgtt tggaaacctg gaaagaatat ttgatcatgg gtctggatgg	5100
ggccacctat gacctcgagg gacaccccca gtacctgctg gactcgaata gctggatcga	5160
ggagatgcc tctgaacgcc tgtgccggag caccgccag cgggcagcct gtgccagct	5220
caacgacttc ctcaggagt atggcactca ggggtgccag gtgtgagggc tgccctccca	5280
cctccgctgg gaggaacctg aacctgggaa ccatgaagct ggaagcactg ctgtgtccgc	5340
tttcatgaac acagcctggg accagggcat attaaaggct tttggcagca aagtgtcagt	5400
gttggc	5406

We claim:

1. A method for diagnosing renal cell carcinoma in a patient comprising steps of:

preparing a composition containing a binding molecule that specifically binds NNMT protein;

contacting the composition with a biological sample from a patient to measure expression level of NNMT protein, wherein the biological sample is a sample selected from the group consisting of a blood sample, a serum sample and a plasma sample; and

comparing the expression level of NNMT protein in the biological sample from the patient with the expression level of NNMT protein in a corresponding biological sample from a normal individual; and

classifying a patient with an elevated expression level of NNMT protein as having renal cell carcinoma.

2. The method according to claim 1, wherein the binding molecule is an antibody and the antibody is one or more

selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a multispecific antibody, a fragment of the antibody, a recombinant antibody, and a chemically modified antibody.

3. The method according to claim 2, wherein the antibody fragment is Fab, F(ab')₂, scFv, Fv, Fab/c, a digestion product of an antibody using a proteolytic enzyme, or an antibody prepared using a recombinant DNA technique.

4. The method according to claim 2, wherein the antibody is a monoclonal antibody or a polyclonal antibody.

5. The method according to claim 4, wherein the monoclonal antibody is prepared using a method of producing a monoclonal antibody comprising immunizing a mammal with the renal cell carcinoma marker and collecting antibody-producing cells, fusing the antibody-producing cells with myeloma cells to establish a hybridoma, and obtaining the monoclonal antibody from the hybridoma.

45

6. The method according to claim 5, wherein the antibody-producing cells are splenocytes (spleen cells), lymph node cells, or peripheral blood cells.

7. The method according to claim 5, wherein the mammal is a rat, a mouse, a rabbit, or a monkey.

8. The method according to claim 5, wherein the myeloma cells are derived from an animal of the same species as the mammal, have drug selectivity, and cannot survive in an HAT

46

selection medium supplemented with hypoxanthine, aminopterin and thymidine in a state of being not fused with splenocytes, but can survive in a state of being fused with splenocytes.

5 9. The method according to claim 5, wherein the renal cell carcinoma marker is a fragment of a full-length protein.

* * * * *

专利名称(译)	肾细胞癌的诊断组合物和试剂盒		
公开(公告)号	US8278058	公开(公告)日	2012-10-02
申请号	US12/672498	申请日	2008-08-06
[标]申请(专利权)人(译)	DCD公司 基诺麦因有限公司		
申请(专利权)人(译)	DCD INC. GENOMINE INC.		
当前申请(专利权)人(译)	DCD INC. GENOMINE INC.		
[标]发明人	KIM DONG SU CHO NAM HOON NA HYUNG JIN CHOI YOUNG DEUK JANG JAE HO KIM HYE KYUNG PARK MO YOEL PARK WON MAN KIM TAE HOON LEE DONG HEE PARK KYUNG MOK		
发明人	KIM, DONG SU CHO, NAM HOON NA, HYUNG JIN CHOI, YOUNG DEUK JANG, JAE HO KIM, HYE-KYUNG PARK, MO YOEL PARK, WON MAN KIM, TAE-HOON LEE, DONG HEE PARK, KYUNG MOK		
IPC分类号	G01N33/53		
CPC分类号	C07K16/3038 C07K16/40 G01N33/5011 G01N33/573 G01N33/57438 G01N33/5017 G01N2333/91017		
优先权	1020070078436 2007-08-06 KR		
其他公开文献	US20100297661A1		
外部链接	Espacenet USPTO		

摘要(译)

本文公开了用于诊断肾细胞癌的组合物和试剂盒。该组合物和试剂盒使用烟酰胺N-甲基转移酶，L-塑性蛋白，促分泌素，NM23A，作为肌动蛋白调节蛋白的CapG和/或C4a过敏毒素作为肾细胞癌标记物。

FIG. 1




FIG. 2

